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ABSTRACT
Increasing evidence suggests the gut microbiome plays an important role in immune
functioning and neurodevelopment. Metabolic products of enteric bacteria, such as short
chain fatty acids and lipopolysaccharides, may alter development and subsequent behaviour.
Altered microbiome composition, including elevated short chain fatty acids, and/or immune
system dysfunction has been observed in children with autism spectrum disorders (ASD).
This thesis describes the effects of prenatal propionic acid (PPA), a short chain fatty acid and
metabolic fermentation product of antibiotic resistant enteric bacteria, and of prenatal
lipopolysaccharide (LPS), a bacterial mimetic and product of enteric bacteria, on a range of
behaviours in male and female neonatal, adolescent and adult rats. Long-Evans rats were
administered PPA or LPS during pregnancy and rat pups were administered PPA in the
second week of life. The first study evaluated the effects of prenatal PPA and LPS, and
postnatal PPA, on developmental milestones in early life and on locomotor activity,
repetitive behaviour, and anxiety-related behaviour in adolescent rats. Secondly,
sensorimotor behaviours were examined using the acoustic startle response and prepulse
inhibition. The final study investigated the effects of prenatal PPA and LPS on social and
related behaviours in neonatal, adolescent, and adult rats. Overall, prenatal and postnatal
treatments subtly altered behaviour in a sex- and test-specific manner. Male and female rats
showed developmental delay in day of eye opening and in acquiring a nest seeking odor
discrimination. Prenatal and postnatal treatments increased anxiety-related behaviour and
altered acoustic startle responses in male and female adolescent rats. Male rats displayed
alterations in social behaviour and locomotor activity that was not observed in female rats,
supporting the male bias seen in ASD. However, female rats showed sensitivity to PPA,
displaying repetitive behaviour, altered acoustic startle response, and decreased prepulse
inhibition. There is evidence to suggest that these behaviours are more severe in females
diagnosed with ASD. These findings demonstrate that the metabolic products of enteric
bacteria, PPA and LPS, may alter development in ways resembling ASD and contribute to
the growing literature on the importance of the gut microbiome and its components on
influencing brain and behaviour.
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Chapter 1
General Introduction
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1.1. Microbiome
The gastrointestinal tract (GI) is home to over a trillion commensal bacteria,
known as the microbiome, that have a symbiotic relationship with their human hosts.
Microbiota benefit from the nutrient-rich environment provided, while the metabolic
activities of the microbiota provide essential products and increase our ability to harvest
nutrients from food (e.g., vitamins, amino acids, short chain fatty acids). These products
can communicate with the central nervous system (CNS) through the enteric nervous
system or via metabolites and/or neurotransmitters released into the bloodstream. The
microbiome plays an important role in maintaining homeostasis and in the development
and functioning of the immune system (Cryan and Dinan, 2012; Nicholson et al., 2012;
Round and Mazmanian, 2009). Various environmental factors can influence microbiome
composition diversity over time during early life. For example, introducing new foods
and antibiotic treatment can alter the bacterial composition of the microbiome, leading to
changes in metabolic activity (Bennet et al., 2002; Cho et al., 2012; Koenig et al., 2011).
Increasingly, attention has focused on how the microbiome and gut bacteria
influence the CNS and the health of the host. Studies using germ-free mice illustrate the
relationship between the microbiome and the CNS. These mice are void of the
commensal bacterial populations that conventional mice have. Alterations in brain and
behaviour include changes in immediate early gene expression, neurotransmitter turnover
and stress responses, and reduced anxiety and social behaviour (Desbonnet et al., 2013;
Foster and Neufeld, 2013; Heijtz et al., 2011; Neufeld et al., 2011; Sudo et al., 2004).
These and other studies with rodents show that a normal bacterial population is necessary
for the development of appropriate humoral and immunological functions.
Maintaining the correct balance of bacterial species is also essential for normal
behavioural, metabolic, and neural functioning. For example, introducing Gram-negative
bacterial species, such as those of food-borne pathogens, increases anxiety and early gene
expression in limbic brain regions involved in anxiety (Bercik et al., 2011; Goehler et al.,
2008; Lyte et al., 2006). Antibiotic treatment has been shown to alter the microbiome
composition and reverse infection induced anxiety (Bercik et al., 2011). With
bidirectional communication between the CNS, immune, and GI systems, GI dysbiosis
has been implicated in inflammatory diseases, obesity, and neuropsychiatric health, such
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as inflammatory bowel disease, depression, and as discussed here, possibly autism (Cryan
and Dinan, 2012; Nicholson et al., 2012).
1.2. Autism spectrum disorders
The prevalence of autism spectrum disorders (ASD) has increased to
approximately 1 in 88 children with a male predominance of approximately 4:1 over
females (Autism and Developmental Disabilities Monitoring Network Surveillance Year
2008 Principal Investigators, 2012). ASD are currently diagnosed through aberrant
behaviours, widely encompassing impairments in communication, social behaviour, and
restricted and repetitive behaviour (DiCicco-Bloom et al., 2006). In the Diagnostic and
Statistical Manual of Mental Disorders (Fifth Edition, DSM-5), this triad will become a
dyad consisting of social communication and repetitive, restrictive behaviour, with
sensory abnormalities being incorporated as a core criterion into the repetitive, restrictive
behaviour domain. Both hyper- and hypo-sensitivities to stimuli across multiple
modalities are reported in ASD (Leekam et al., 2007; Marco et al., 2011). Multiple comorbidities have been observed in patients with ASD, including anxiety disorders,
seizures, and gastrointestinal disturbance, suggesting that ASD is not merely a disorder of
the brain but of dysfunction in multiple organ systems (Herbert et al., 2006; Tuchman and
Rapin, 2002; Simonoff et al., 2008; Williams et al., 2011).
1.2.1. Etiology of ASD
While the exact causes of ASD are unknown, there is clearly a genetic component
to the development of the disorders. Multiple candidate genes have been identified
through linkage analyses and de novo copy number variations that have been found,
implicating a number of processes including synaptic development and
neurotransmission, cell signalling and transcription, and immune and mitochondrial
function (Cook, Jr. and Scherer, 2008; Geschwind, 2011; Szatmari et al., 2007). Despite
these discoveries, known genetic factors exclusively account for approximately 10-20%
of ASD cases (Hallmayer et al., 2011; Scherer and Dawson, 2011). Furthermore,
concordance rates among monozygotic twins range from 50-90% (Bailey et al., 1995;
Hallmayer et al., 2011). This has led to the acceptance that the environment influences
the development of ASD, likely acting on underlying genetic susceptibilities during
prenatal or early postnatal life (Herbert, 2010).
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Multiple risk factors have been suggested to increase the risk for ASD such as
preterm birth, maternal and paternal age, and pre-eclampsia/eclampsia (Kolevzon et al.,
2007; Mann et al., 2010). A number of environmental agents have been identified which
can increase the risk of ASD, including thalidomide, ethanol, and valproic acid (Arndt et
al., 2005). Lastly, the immune system has garnered much attention as prenatal infections
increase the risk of developing ASD, with viral infection in the first trimester and
bacterial infection in the second trimester being associated with ASD (Atladottir et al.,
2010).
1.3. Immune abnormalities in ASD
Immune system abnormalities, both central and peripheral, have been found in
children with autism and their families. A family history of autoimmune disease has been
associated with families of children with ASD (Atladottir et al., 2009; Croen et al., 2005).
Plasma of children with ASD has shown an increase in a number of cytokines and
chemokines that have been associated with severity of behaviours, including interleukin
(IL)-1 , IL-6, IL-17, IL-23, and monocyte chemoattractant protein (MCP)-1 (Ashwood et
al., 2011a; Ashwood et al., 2011b; Enstrom et al., 2009). Additionally, alterations in the
adaptive and innate cellular immune responses have been observed in children (see Onore
et al., 2012 for review). Infections during pregnancy or early life in genetically
susceptible populations may contribute to altered neurodevelopmental processes via
release of pro-inflammatory cytokines. The balance between pro- and anti-inflammatory
cytokines is important for normal development (e.g., neural cell differentiation and
migration), and dysregulation in this balance may have adverse consequences (Deverman
and Patterson, 2009). Postmortem analysis of brain tissue of autistic patients has revealed
a neuroinflammatory response with increased activated microglia and astrocytes and
proinflammatory cytokines (Li et al., 2009; Vargas et al., 2005). Increases in the
proinflammatory cytokine IL-6 has been suggested to alter neural processes in autism,
mediating the effects of maternal immune infection and neuroinflammatory responses
(Parker-Athill and Tan, 2010; Wei et al., 2013).
1.4. Gastrointestinal abnormalities in ASD
A subset of patients with ASD have gastrointestinal (GI) symptoms, with the
severity of autistic behaviours associated with the severity of GI dysfunction (Adams et
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al., 2011b). These symptoms may be lessened by alterations in diet in some cases
(Knivsberg et al., 2002; Pennesi and Klein, 2012). GI symptoms can include increased
permeability or inflammation of the intestinal tract, alterations in gut motility, and food
allergies/sensitivities (deMagistris et al., 2010; Horvath and Perman, 2002; Jyonouchi et
al., 2002; White, 2003). Multiple changes in immune and GI functioning have been
observed in children with ASD and GI symptoms, including increases in intestinal proinflammatory cytokines (Ashwood et al., 2004; Jyonouchi et al., 2005; Jyonouchi et al.,
2011).
Additionally, immune responses can alter the composition of the microbiome of
the GI tract, which may contribute to intestinal inflammation and development or
maintenance of ASD (Bartlett and Gerding, 2008; Bennet et al., 2002). Indeed, abnormal
levels of bacteria flora have been found in the intestinal tract and feces of children with
ASD and GI symptoms, including Clostridia, Bacteroidetes, and Desulfovibrio (Finegold
et al., 2002; Finegold et al., 2012; Parracho et al., 2005), with other bacterial species
implicated as well (Williams et al., 2011; Williams et al., 2012). Interestingly, these
anaerobic bacteria are antibiotic-resistant. As such, repeated infections in early life
treated with antibiotics may provide an enteric environment that promotes overgrowth of
these bacteria (Cho et al., 2012; Finegold et al., 2012) and an association has been made
between antibiotic use and autism (Parracho et al., 2005). Alternatively, prenatal
infection and/or, in addition, GI disturbances in pregnancy may alter gut bacteria
composition. Products of these bacteria as a result of their metabolic activities include
elevated levels of a number of compounds, including lipopolysaccharide and short chain
fatty acids (SCFA), apart from the amounts of these compounds released from normal
carbohydrate metabolism by bacteria in general (Finegold et al., 2010). These compounds
may induce inflammatory responses, alter neurodevelopment, and act on the CNS to
influence behaviour.
1.5. Environmental animal models of ASD
1.5.1. Maternal immune activation (MIA)
Studies that administer agents that induce an immune response to pregnant
rodents are used to investigate the role of prenatal infectious processes in the
development of neurodevelopmental disorders such as autism and schizophrenia
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(reviewed in Meyer, 2013; Patterson, 2011). To activate the maternal immune response in
the absence of a pathogen, the viral mimetic, polyinosinic:polycytidylic acid (poly I:C)
or the bacterial mimetic, lipopolysaccharide (LPS) are widely used. These agents activate
Toll-like receptors 3 and 4, respectively, to induce an inflammatory response and trigger
the release of pro-inflammatory cytokines (Akira and Takeda, 2004).
LPS is the major component of the cell wall of Gram-negative bacteria but is
present in low amounts in the GI tract as a product of enteric bacteria. It has been shown
that the composition of the gut microbiome and increased levels of LPS can have
detrimental effects. For example, infection of germ-free mice with the Gram-negative
enteric pathogen (Campylobacter jejuni) altered anxiety-like behaviour and was
associated with increased early gene expression in brain regions implicated in anxiety
(Goehler et al., 2008; Lyte et al., 2006). Additionally, systemic LPS administration, that
results in clinically relevant plasma concentrations, induced intestinal inflammation and
increased intestinal cell wall permeability in rats and mice similar to that seen in gut and
intestinal disorders (Ge et al., 2000; Guo et al., 2013; Tokes et al., 2011; Yue et al.,
2012). Inflammation and increased permeability of the GI tract can result in the further
release of cytokines and LPS into the bloodstream to exact effects on the CNS (de Theije
et al., 2011), including triggering brain endothelial cells to release cytokines (Verma et
al., 2006).
Prenatal administration of LPS and poly I:C produces changes in behaviour in
adult male and female offspring, with limited studies, to date, in adolescent offspring.
Timing and dose of MIA can influence the nature of the behavioural change and cytokine
release (Boksa, 2010; Meyer et al., 2006). Results of a variety of studies have shown that
offspring of MIA dams displayed increased anxiety behaviour, decreased exploratory
behaviour, decreased social interaction and approach, and decreased sensorimotor gating
(Fortier et al., 2007; Shi et al., 2003; Smith et al., 2007). Alterations in dopamine and
GABA neurotransmission and white matter changes have also been observed (Baharnoori
et al., 2013; Meyer, 2013; Oskvig et al., 2012; Vuillermot et al., 2010). Giovanoli et al.
(2013) prenatally administered a low dose of the viral mimetic, poly I:C, which did not
result in changes to behaviour in adult offspring unless combined with a stress protocol in
early adolescence (P30-40). It is becoming apparent that prenatal immune activation may
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act to predispose individuals to a number of neuropsychiatric conditions, or act on preexisting genetic predispositions (Meyer, 2013). Termed the double hit hypothesis, the
idea of genetic predisposition leaving individuals vulnerable to an environmental trigger
later in life that results in manifestation of a disorder was originally proposed for
schizophrenia (Bayer et al., 1999).
The mechanisms associated with MIA induced alterations in brain and behaviour
of offspring are beginning to be elucidated. It appears that toxins and/or cytokines gain
access to the fetus, as maternal virus is not detected in the fetus (Bloise et al., 2013; Shi et
al., 2005). Cytokines, particularly IL-6, have been shown to induce further cytokine
release and activate intracellular pathways in the placenta to alter gene expression and
growth protein levels (Hsiao and Patterson, 2011), while blocking IL-6 has reversed
behavioural impairments in MIA mice (Smith et al., 2007). Gene expression changes in
offspring include upregulation of cellular stress genes and downregulation of genes
associated with neurogenesis, neural migration, and neurotransmission (Garbett et al.,
2012; Oskvig et al., 2012).
1.5.2. Propionic acid (PPA) model
Propionic acid (PPA) is a short chain fatty acid (SCFA), and is a metabolic
product of enteric gut bacteria (Finegold et al., 2002). Physiologically, PPA can cross the
gut-blood and blood-brain barriers (BBB). G-protein coupled receptors, GPR41 and
GPR43, are specific for SCFAs and located in intestine, immune and blood endothelial
cells (Brown et al., 2003; Bindels et al., 2013), while monocarboxylate transporters are
located at the BBB for SCFAs (Pierre and Pellerin, 2005). SCFAs are endogenous and in
normal physiological conditions, PPA and other SCFAs fulfill a number of important
roles in cell metabolism. For example, SCFA are involved in energy utilization from the
diet via activation of GPR43, are used as substrates themselves in cell metabolism, and
regulation of the immune system (Al-Lahham et al., 2010; Brestoff and Artis, 2013;
Kimura et al., 2013).
It has been proposed that elevated levels of PPA may act as an environmental
trigger and contribute to the development of ASD. Elevated levels of fecal SCFAs have
been measured in children with ASD (Wang et al., 2012) and a recent case report was
published of a child with propionic acidemia and autism (Al-Owain et al., 2013). Altered
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propionic acid (PPA) metabolism occurs in propionic acidemia, a neurodevelopmental
disorder that clinically resembles some aspects of autism. Children with this disorder
have a deficient enzyme resulting in elevated levels of PPA along with developmental
and cognitive delay, seizures, and stereotyped movements (Feliz et al., 2003).
PPA can elicit diverse effects on the CNS that could drastically alter neural
processes, including changes in neurotransmitter synthesis and release, oxidative stress
and mitochondrial function, immune activation, and gene expression (DeCastro et al.,
2005; Inoue et al., 2012; Le Poul et al., 2003; Parab et al., 2007; Wajner et al., 2004).
Metabolic dysfunction in mitochondria and oxidative stress have been found in children
with ASD, and associated with severity of behavioural symptoms (Adams et al., 2011a;
Rossignol and Frye, 2012).
PPA, similar to valproic acid (VPA), is capable of acting as a histone deacetylase
inhibitor to elicit epigenetic changes in gene expression, and both are fatty acids that can
interfere with mitochondria cell metabolism (Brass, 1992; Coulter, 1991; Frye et al.,
2013). VPA is a common antiepileptic drug and with use in pregnancy, there is a risk for
congenital malformations (e.g., spina bifida) and for ASD to develop in children,
specifically when used in the first trimester (Bromley et al., 2008; Jentink et al., 2010).
Animal studies administering VPA during a comparable window of vulnerability
(gestation day 12 in rats) produce offspring that display physical malformations,
developmental delay, and behavioural deficits, including sensory impairments, and
decreases in exploratory behaviour, social play/interaction, and prepulse inhibition (Favre
et al., 2013; Roullet et al., 2013). VPA through its effects as a histone deactylase inhibitor
and can alter gene expression, with administration in rodents both increasing and
decreasing expression of ASD-implicated genes (Kolozsi et al., 2009; Okada et al., 2005;
Yu et al., 2009).
Changes in brain and behaviour resembling those observed in ASD have been
shown in rats receiving central PPA, providing face validity for a rodent model. The
majority of previous studies investigating the effects of PPA on brain and behaviour have
been in adult male rats administered PPA centrally into the lateral ventricles with some
studies of peripheral administration. Repeated infusions of PPA produced kindled
seizures, increased locomotor activity, decreased social behaviour, and impaired reversal
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of the Morris water maze in adult male rats (Shultz et al., 2008; Shultz et al., 2009;
Thomas et al., 2012), with decreased social behaviour and impaired maze reversal in
adolescent male rats (MacFabe et al., 2011).
Peripheral administration of PPA in adolescent and male adult rats has aversive
properties, and produced decreased social behaviour and increased anxiety (Benzaquen et
al., 2010; Ossenkopp et al., 2011; Shams et al., 2009). Brains of animals that received
central PPA showed an innate neuroinflammatory response, oxidative stress and
mitochondrial dysfunction, and lipid alterations, all of which have been associated with
ASD (Frye et al., 2013; MacFabe et al., 2007; MacFabe et al., 2008; Thomas et al., 2010;
Thomas et al., 2012). As ASD are childhood disorders and are more prevalent in males,
the next step in garnering evidence for PPA as an environmental trigger of ASD is to
conduct studies on younger animals and investigate both males and females for possible
sex differences.
1.6. Present studies
The goal of my thesis was to investigate the effects of metabolic products,
associated with enteric bacteria and an altered gut microbiome composition, on
neurodevelopment and subsequent behaviour. Immune system activation can alter the
composition of the microbiome of the gastrointestinal tract (Bartlett and Gerding, 2008;
Bennet et al., 2002). Repeated environmental insults (e.g., immune) in prenatal and/or
early postnatal life may lead to chronic inflammation, altering the gut microbiome, and
contribute to the development of ASD. Thus, I administered the enteric metabolic
products PPA and LPS prenatally to rats to mimic subtle alterations in the production of
gut metabolites that may result from a low-grade bacterial infection and the resulting
inflammatory response.
To investigate the effects of an early life infection or insult that could alter the gut
microbiome, a second ‘hit’ of PPA in the second postnatal week was given to mimic
postnatal production of SCFA from the developing gut microbiota (Midtvedt and
Midtvedt, 1992; Nafday et al., 2005). Manipulations in development leaving animals
susceptible to later environmental insults are not unheard of, with evidence for the double
hit hypothesis observed in neonatal immune research. Neonatal LPS in the first week of
life produced altered behaviour in rats upon a second environmental insult during
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adolescence or adulthood (Tenk et al., 2008; Walker et al., 2009). This approach has not,
to date, been used in previous animal models of ASD. However, not all maternal
infections result in neurodevelopmental disorders and repeated insults throughout
development may be required. It is thus possible that prenatal treatment with LPS or PPA
may leave offspring vulnerable to the effects of postnatal PPA exposure.
Specifically, in this thesis I addressed the following questions: 1. Does
administration of propionic acid in development alter subsequent behaviour in adolescent
male and female rats? 2. Does prenatal administration of a low dose of
lipopolysaccharide alter subsequent behaviour in adolescent male and female rats? and 3.
Based on the double-hit hypothesis, will a combination of prenatal and postnatal
treatments exacerbate subsequent behaviour altered by prenatal treatment or allow
alterations in behaviour to appear that would not otherwise occur with either treatment
alone? I used a range of behavioural tests to characterize the effects of PPA and LPS on
offspring.
Developmental milestones, locomotor activity, and anxiety (Chapter 2), reactivity
to acoustic startle and sensorimotor gating (Chapter 3), and social and related behaviour
(Chapter 4) were assessed. I hypothesized that prenatal PPA and LPS would produce
developmental delay in milestones, decrease sensorimotor gating, and decrease social
behaviour. I also predicted alterations in locomotor activity and acoustic startle responses
with prenatal PPA, either increases or decreases. Where prenatal effects occurred, I
hypothesized that a second hit with postnatal PPA would exacerbate behavioural changes.
These studies demonstrate that metabolic products of the gut microbiome, PPA and LPS,
alter neurodevelopment to produce sexually dimorphic behavioural changes in offspring
that resemble some of the behaviours observed in ASD.
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Chapter 2
Sex differences in the effects of prenatal lipopolysaccharide or the bacterial
metabolic product, propionic acid on postnatal development, and locomotor activity
and anxiety in male and female adolescent rats
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2.0. Summary
Alterations in the composition of the gut microbiome and/or immune system function
may have a role in the development of autism spectrum disorders (ASD). The current
study examined the effects of prenatal and early life administration of lipopolysaccharide
(LPS), a bacterial mimetic, and the short chain fatty acid, propionic acid (PPA), a
metabolic fermentation product of enteric bacteria, on developmental milestones,
locomotor activity, and anxiety-like behaviour in adolescent male and female offspring.
Pregnant Long-Evans rats were injected once a day with PPA (500 mg/kg SC) on
gestation days G12-16, LPS (50 g/kg SC) on G15-16, or vehicle control on G12-16 or
G15-16. Male and female offspring were injected with PPA (500 mg/kg SC) or vehicle
twice a day, every second day from postnatal days P10-18. Physical milestones and
reflexes were monitored in early life with prenatal PPA and LPS inducing delays in eye
opening. Locomotor activity and anxiety was assessed in adolescence (P40-42) in the
elevated plus maze and open-field. Prenatal and postnatal treatments altered behaviour in
a sex-specific manner. Prenatal PPA decreased time spent in the centre of the open-field
in males and females while prenatal and postnatal PPA increased anxiety behaviour on
the EPM in female rats. Prenatal LPS did not influence locomotor activity or anxiety-like
behaviour. Evidence for the double hit hypothesis was seen as females receiving a double
hit of PPA (prenatal and postnatal) displayed increased repetitive behaviour in the openfield. These results provide evidence for the hypothesis that by-products of enteric
bacteria metabolism may contribute to ASD, altering development and behaviour in
adolescent rats similar to that observed in ASD and other neurodevelopmental disorders.
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2.1. Introduction
Autism spectrum disorders (ASD) are neurodevelopmental disorders with roughly
4 males diagnosed for every 1 female. ASD comprise a number of behavioural
symptoms, including impairments in communication, social behaviour, sensory
abnormalities, and restricted and repetitive behaviour (DiCicco-Bloom et al., 2006).
Repetitive behaviour can include motor patterns such as hand flapping or repetitive use of
objects while restricted interests may include an insistence on sameness or resistance to
change (Leekam et al., 2011; Richler et al., 2007). In many children and adults with
ASD, psychiatric disorders, gastrointestinal symptoms and epilepsy comorbidly occur
(Tuchman and Rapin, 2002; Simonoff et al., 2008; Williams et al., 2011).
It is becoming well established that both genetics and environmental factors
contribute to the development and expression of ASD. A number of genes involved in
immune function, mitochondrial function, and neural circuit formation have been
implicated (Cook, Jr. and Scherer, 2008; Szatmari et al., 2007). However, known genetic
factors discovered thus far account for 10-20% of ASD and concordance rates among
monozygotic twins are less than 100%, suggesting an important role for environmental
risk factors which act on the genetic susceptibilities (Hallmayer et al., 2011; Anderson et
al., 2008).
The gastrointestinal tract (GI) is home to over a trillion commensal bacteria,
known as the microbiome, that have a bidirectional relationship with the central nervous
system and contribute to normal immune system development and homeostasis in both
humans and rodents (see Foster and Neufeld, 2013). GI dysbiosis has been implicated in
inflammatory diseases and neuropsychiatric health (Brestoff and Artis, 2013; Cryan and
Dinan, 2012; Nicholson et al., 2012). There is suggestive evidence that imbalances in the
composition of the microbiome may also contribute to the development or maintenance
of ASD in children with findings of abnormal levels of bacteria flora, including
Clostridia, Bacteroidetes, and Desulfovibrio, in the GI tract of autistic children (Finegold
et al., 2002; Finegold et al., 2012; Parracho et al., 2005). These anaerobic bacteria are
antibiotic-resistant. As such, repeated early infections in postnatal life treated with
antibiotics may provide an enteric environment that promotes overgrowth of these
bacteria resulting in intestinal inflammation (Cho et al., 2012; Finegold et al., 2012).
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Metabolic products of these enteric bacteria include the short chain fatty acids
(SCFA, from carbohydrate metabolism) (Finegold et al., 2010), which are able to enter
circulation and may alter immune function and/or exacerbate ASD behaviours. In fact,
propionic acidemia is a neurodevelopmental metabolic disorder characterized by elevated
levels of the SCFA, propionic acid, (PPA) that clinically resembles some aspects of
autism (Feliz et al., 2003). A case study of autism occurring comorbidly with propionic
acidemia has been reported (Al-Owain et al., 2013) while elevated fecal levels of SCFA
have been found in ASD children (Wang et al., 2012). Although PPA is necessary for
normal immune and physiological functioning, elevated levels may result in disruptive
effects (Brestoff and Artis, 2013). It has been proposed that PPA, produced by enteric
bacteria, may be a potential environmental factor in the development of ASD. Central
administration of PPA has produced hyperactivity and decreased social behaviour in
adult male rats (MacFabe, 2012). High levels of SCFA in the hindgut of rats and
peripheral PPA injections have also produced changes in activity, anxiety-like, and social
behaviour, consistent with ASD (Hanstock et al., 2004; Ossenkopp et al., 2012).
Neuroinflammatory and metabolic changes, implicating oxidative stress and
mitochondrial dysfunction, have been observed in a subset of patients with ASD and in
rats given central PPA (Frye et al., 2013; MacFabe et al., 2008; Rossignol and Frye,
2012).
Immune dysfunction may increase the risk for ASD with alterations in the
adaptive and innate cellular immune responses having been observed in children (see
Onore et al., 2012 for review). Viral infection in the first trimester and bacterial infection
in the second trimester have also been associated with ASD (Atladottir et al., 2010).
Maternal immune activation (MIA) in rodents is used to investigate the role of the
immune system in development, including its role in anxiety, schizophrenia and ASD. A
variety of agents, including poly I:C (a viral mimetic) and lipopolysaccharide (LPS),
induce an inflammatory response. LPS, a bacterial mimetic, is the major component of
the cell wall of Gram-negative bacteria and is also a by-product of enteric bacteria
metabolism. Valproic acid (VPA), a common epilepsy treatment, has been shown to
increase the risk of ASD. MIA and prenatal administration of VPA produces
developmental delay and behavioural deficits in rodents (see Boksa, 2010; Roullet et al.,
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2013). Brusque et al., (1999) administered daily PPA throughout postnatal life (days 6-28
of life) and reported developmental delay and motor impairment. Interestingly, VPA is
converted to PPA. However, to date, there have been no studies examining the effects of
prenatal PPA administration on behaviour in either male or female offspring.
Prenatal and postnatal administration of immune stimulants (such as LPS) has
shown to result in changes in anxiety-like and exploratory behaviour in adult male and
female rats. Increased anxiety in the elevated plus maze have been shown in male and
female adult offspring (Enayati et al., 2012; Lin et al., 2012; Walker et al., 2009).
Assessment of open-field activity has yielded mixed results, with decreased exploration
(Shi et al., 2003; Smith et al., 2007), no change in activity (Fortier et al., 2004; Vorhees et
al., 2012), or hyperactivity (Howland et al., 2012) being observed. Studies of MIA with
adolescent rats are fewer in numbers. Examination of possible sex differences in younger
animals is particularly relevant in view of the predominance of ASD in young males.
Studies report increased anxiety on the elevated plus maze in adolescent males and
decreased exploration in the open-field in adolescent males and females, with some
studies reporting no change in behaviour (Enayati et al., 2012; Howland et al., 2012;
Oskvig et al., 2012; Schwendener et al., 2009; Vorhees, 1987). While there is increasing
attention on investigating possible sex differences following MIA, most published
studies, to date, are with male rodents.
Results of a number of studies have also shown that the effects of postnatal LPS
on subsequent behaviour do not manifest themselves unless a second environmental
insult (e.g., restraint stress or LPS injection) is experienced in adulthood (e.g., Tenk et al.,
2008, Walker et al., 2009). Postnatal immune activation confers a susceptibility to later
systemic insults that result in abnormal behaviour. This idea, termed the double hit
hypothesis, was put forward to describe the genetic predisposition in schizophrenia that
may confer vulnerability to an environmental trigger later in life that results in emergence
of the disorder (Bayer et al., 1999). Genetics may also confer a susceptibility to prenatal
or postnatal environmental insults in ASD, or it may be that more than one insult may be
required as is the case in repeated infections in early life. Acute or repeated immune
responses may alter the composition of the gut microbiome, increasing production of
potential aversive metabolic products (Bartlett and Gerding, 2008; Bennet et al., 2002).
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Thus, it is possible that prenatal treatment with PPA may leave offspring vulnerable to
the effects of postnatal PPA treatment. Prenatal LPS may also leave offspring vulnerable
to postnatal PPA, as LPS is also a product of enteric bacteria. This approach of multiple
environmental insults has not been used in animal models of ASD thus far.
The present study investigated the effects of prenatal treatment with the immune
stimulant, LPS, and the microbiome associated gastrointestinal factors, PPA, on postnatal
developmental milestones, open-field activity and anxiety-like behaviour in adolescent
male and female offspring. In addition, the effects of a second ‘hit’ of PPA in the second
postnatal week were examined. Specifically, the effects of prenatal LPS, prenatal PPA,
and postnatal PPA administration on the development and behaviour of adolescent male
and female rats are compared. It was hypothesized that prenatal LPS would increase
anxiety-like behaviour in offspring and that prenatal PPA would increase locomotor
activity and anxiety-like behaviour in offspring. Combinations of prenatal and postnatal
treatments, prenatal LPS with postnatal PPA and prenatal PPA with postnatal PPA, are
included to assess whether behavioural effects will be magnified compared to that seen
after either treatment alone. Developmental delay was observed in male and female rats
with prenatal PPA and LPS, while increased anxiety-like behaviour was sex- and
treatment-specific.
2.2. Method
2.2.1. Animals
Twelve primiparous female Long-Evans rats weighing between 270-310 g were
mated with adult male Long-Evans rats (375-550 g, Charles River, Canada) for a total of
12 litters. Females were paired overnight with a male the night before behavioural estrus.
Sperm present on a vaginal smear (hematoxylin & eosin stain) the morning after pairing
indicated successful mating and this was designated gestational day 0 (G0). Dams were
housed individually in standard polypropylene cages (45 x 22 x 20 cm) with ad libitum
access to both food (ProLab RMH 3000) and water. A 12:12 h light:dark cycle (lights on
at 0700 h) was maintained in a temperature controlled colony room (21 ± 2°C). Litters
were born on G22 (designated as postnatal day (P) 0), toe-clipped for identification, and
were weaned at P21 (M = 14.17 pups, SD = 2.41). On P21, pups were weaned and
randomly culled to a maximum of 10 animals per litter (5 males, 5 females). Weaned rats
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were housed in same-sex, same-postnatal drug groups of 2 or 3 in standard polypropylene
cages under the same conditions as dams. All behavioural testing took place during the
light phase and animals were monitored (e.g., body weight) during testing. Procedures
were approved by the University of Western Ontario Animal Use Subcommittee and
were in accordance with the Canadian Council of Animal Care (CCAC) guidelines.
2.2.2. Prenatal LPS and PPA administration
Sodium propionate (PPA, P1880, Sigma Chemical, St. Louis, MO, USA) was
dissolved in 0.1 M phosphate buffered saline and administered at a dose of 500 mg/kg
subcutaneously (SC, pH corrected to 7.4 with concentrated HCl) once a day on G12-16
for a total of 5 injections. Injections started on G12 to mimic the VPA and MIA models
of ASD (Schneider and Przewlocki, 2005). Multiple injections were administered given
the short half-life of PPA (20 min) (Brusque et al., 1999). A low dose (compared to
previous studies) was used in order to be comparable to the relatively low dose of
elevated PPA resulting from an altered microbiome composition. Lipopolysaccharide
(LPS from E. coli serotype 0111:B4, L2630, Sigma Chemical, St. Louis, MO, USA) was
dissolved in 0.1 M phosphate buffered saline and administered SC at a low dose of 50
g/kg on G15 and G16. Prenatal LPS administered at this time has been previously
shown to increase anxiety-like behaviour (Enayati et al., 2012) and decrease sensorimotor
gating (Fortier et al., 2007). An equivalent volume of phosphate buffered saline was
injected SC as a vehicle control (2 mL/kg) to yield two control groups, either on G15 and
G16 (2VEH) or on G12-16 (5VEH). All maternal injections were administered between
the shoulder blades.
2.2.3. Postnatal PPA administration
As synaptogenesis occurs during the first 3 weeks of postnatal life in rats (Rice
and Barone Jr, 2000), on P10, 12, 14, 16, and 18, male and female pups were injected
twice a day SC with either PPA (500 mg/kg, pH = 7.4) or equivalent volumes of
phosphate buffered saline vehicle (VEH, 5mL/kg) to correspond with an environmental
insult in early human life. Half of each litter was injected with postnatal PPA and the rest
with VEH. Injections took place at 0930 h (between the shoulder blades) and 1530 h
(between the haunches).
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2.2.4. Experimental procedure
Table 2.1 provides a summary of drug treatments and group numbers of pups
monitored for developmental milestones. Litters were weaned to a maximum of 10
animals and these animals underwent behavioural testing in adolescence on P40, 42
(Table 2.2). The prenatal and postnatal injection schedule yielded the following treatment
combinations for each sex: No drug treatment except vehicle (prenatal 2VEH or 5VEH
with postnatal VEH); Prenatal treatment alone (prenatal LPS or PPA with postnatal
VEH); Postnatal PPA alone (prenatal 2VEH or 5VEH with postnatal PPA); Prenatal and
Postnatal treatment combined (prenatal LPS or PPA with postnatal PPA).
2.2.4.1. Developmental milestones
The body weights of pups were monitored daily for the first 20 days of life. The
following developmental milestones were assessed for day of appearance: Righting reflex
(P2-6): pups were placed on their back and given 30 s to turn onto stomach with all limbs
outstretched from body; Pinna detachment (P2-4): bilateral pinna unfolding completely
from head; Incisor eruption (P7-13): both upper and lower; Eye opening (P12-16): scored
as 0 = both eyes closed, 1 = one eye open, 2 = both eyes open; Negative geotaxis (P7-10):
time (s) to rotate 180° on a 30° incline when placed head down (assesses vestibular
function and motor development) (Altman and Sudarshan, 1975) with each pup given a
maximum of 3 – 60 s trials to complete the task; Free-fall righting reflex (P15): pups
were held 35 cm above a padded surface with back facing down and released. A
successful trial occurred when the pup landed on its stomach and all limbs were
outstretched, with 3 successive trials (15 s apart) yielding a possible maximum score of 3.
2.2.4.2. Elevated plus maze (EPM) – P40
The EPM was made of wood and painted grey with non-toxic paint. The
apparatus consisted of two opposite open arms (54 x 12 cm) with no sides or ends and
orthogonal to two enclosed arms with sides and ends (54 x 12 x 48 cm). The four arms
extended from a centre platform (12 x 12 cm) and the apparatus was raised 50 cm from
the floor. An overhead camera connected to a television and DVD-R recorded behaviour
for later scoring.

29

Table 2.1. Summary of treatment groups tested for developmental milestones

Prenatal treatment
LPS
5VEH
8
8

(M)

2VEH
8

PPA
12

36

(F)

9

12

12

10

43

(M)

10

8

11

14

43

(F)

11

14

12

11

48

38

42

43

47

170

VEH
Postnatal
treatment
PPA

Total

Note: Numbers in the table represent number of animals per group for males (M) and
females (F). There were 3 litters in each of the 4 prenatal groups (2VEH, 5VEH: 2 or 5
injections of phosphate buffered saline vehicle on G15-16 or G12-16, respectively; LPS:
Lipopolysaccharide, 50 ug/kg on G15-16; PPA: Propionic acid, 500 mg/kg on G12-16).
Postnatal treatment during the second week of rat pups’ life consisted of phosphate
buffered saline vehicle (VEH) or propionic acid (PPA).
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Table 2.2. Summary of treatment groups used for behavioural testing
Prenatal treatment
LPS
5VEH
6
6

(M)

2VEH
6

PPA
6

24

(F)

6

6

6

6

24

(M)

8

8

9

9

34

(F)

8

9

9

9

35

28

29

30

30

117

VEH
Postnatal
treatment
PPA

Total

Note: Numbers in the table represent number of animals per group for males (M) and
females (F). There were 3 litters in each of the 4 prenatal groups (2VEH, 5VEH: 2 or 5
injections of phosphate buffered saline vehicle on G15-16 or G12-16, respectively; LPS:
Lipopolysaccharide, 50 ug/kg on G15-16; PPA: Propionic acid, 500 mg/kg on G12-16).
Postnatal treatment during the second week of rat pups’ life consisted of phosphate
buffered saline vehicle (VEH) or propionic acid (PPA). A maximum of 5 males and 5
females (3 postnatal PPA, 2 postnatal VEH for each sex) per litter were included in
behavioural testing. Testing took place on P40 and P42.
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Testing took place on the afternoon of P40. Animals were recorded for 5 minutes
and placed on the centre platform facing an open arm to begin the test. After each animal,
the maze was cleaned with a 20% alcohol solution. Measures assessed included the
number of entries onto open and closed arms and time spent (s) on open and closed arms.
Percent time in open arms was taken as a measure of anxiety (time spent in open
arms/time spent in open arms + time spent in closed arms x 100).
2.2.4.3. Open-field test – P42
Locomotor activity was monitored using eight Versamax Animal Activity
Monitors (AccuScan Model DCM-8, Columbus, OH, USA), each consisting of a
Plexiglas open field chamber (40 cm x 40 cm x 30.5 cm), and a Plexiglas lid with air
holes. Infrared beams surrounding each chamber recorded horizontal and vertical
locomotor activity as beam breaks, from which locomotor measures were compiled
(Ossenkopp and Kavaliers, 1996). There were 16 infrared beam sensors on each side
(2.54 cm apart, 4.5 cm from the floor) for horizontal movements, while on two opposite
sides, 16 upper beams were located 15 cm above the chamber floor to assess vertical
movements. Additionally, the VersaMax software separated the open-field into discrete
periphery (7.5 cm wide border) and centre (30 x 30 cm square) zones to measure
thigmotaxis (tendency of animals to stay close to the walls, an indication of anxiety)
(Treit and Fundytus, 1988).
Animals were placed in the novel open-field for 60 min on P42 to assess any
changes in locomotor activity. Horizontal activity measures analyzed were: total distance
(TD) − total horizontal distance (cm); horizontal movement time (MT) − amount of time
(s) an animal was engaged in horizontal movement; number of horizontal movements
(NM) − number of horizontal movements separated by 1 s stop time. Vertical activity
measures analyzed were: vertical movement time (VT) − amount of time (s) an animal
spent in a vertical position; number of vertical movements (VM) − number of vertical
movements separated by 1 s stop time. Repetitive activity was measured as number of
revolutions (clockwise and counterclockwise) - number of times an animal runs in a
clockwise or counterclockwise circle of at least 2 inches in diameter. Duration spent (s)
in the periphery and centre was measured, and locomotor activity was corrected for time
spent in each zone (TD, MT, VM, VT).
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2.2.5. Statistical analysis
All analyses were performed with IBM Statistics 20 (formerly Statistical Package
for the Social Sciences, SPSS). As pups within a litter are not independent samples, the
effects associated with belonging to a litter and being raised in a litter must be accounted
for. To do this, linear mixed models were used for each of the dependent variables, with
Litter used as a subject variable. Fixed factors in all models were: Sex, Prenatal drug,
Postnatal drug while litter size was used as a covariate. For body weight, negative
geotaxis, and eye opening, Day was also included as a factor. LSD post-hocs were
performed. Significance was set to

= 0.05.

2.3. Results
2.3.1. Development
2.3.1.1. Body Weight: Postnatal
Weight was monitored daily for the first 20 days of life (P0-P19). All pups gained
weight across days, F(19,3072) = 3077, p < 0.001, and male pups weighed significantly
more than female pups, F(1,3072) = 88.02, p < 0.001 (Figure 2.1A-D). There was a
significant Sex x Prenatal drug x Postnatal drug interaction, F(3,3072) = 6.20, p < 0.001.
Postnatal PPA treated male pups were significantly heavier than postnatal VEH treated
male pups (p < 0.001) on P13-19 in the prenatal PPA and 2VEH groups, ps < 0.05
(Figure 2.1A-B). Postnatal PPA treated female pups were significantly lighter than
postnatal VEH treated female pups (p < 0.001) with individual days failing to reach
significance in the prenatal LPS group (Figure 2.1C-D).
2.3.1.2. Body Weight: Adolescence
Weight was monitored on P39, P45, 47, 49, and 51 (data from P45-51 presented
in Chapter 3). All animals gained weight across days, F(4,419) = 298.04, p < 0.001, with
males weighing significantly more than females, F(1,417) = 1841.06, p < 0.001. A
significant Sex x Prenatal drug x Postnatal drug interaction, F(3,417) = 3.36, p = 0.019,
indicated that in prenatal 2VEH animals, postnatal PPA adolescent males weighed
significantly more than postnatal VEH males, p < 0.001 (P39 NS, P45-51 ps < 0.05), with
no significant effect of postnatal drug in adolescent females (see Figure 2.2).
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Figure 2.1. Body weight (g) for male and female offspring from postnatal days 10-19.
A-B: Males. C-D: Females. Rats were prenatally exposed to either lipopolysaccharide
(LPS) on G15-16, propionic acid (PPA) on G12-16, or their respective phosphate
buffered saline controls (2VEH and 5VEH). Postnatal treatment, either PPA or VEH, was
administered 2x/day every other day from P10-18. Males receiving postnatal PPA
weighed significantly more than postnatal VEH treated males within prenatal PPA and
2VEH groups, while females receiving postnatal PPA weighed significantly less than
postnatal VEH treated females within the prenatal LPS group (ps < .05). Error bars
represent S.E.M. Refer to Table 2.1 for sample sizes.
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Figure 2.2. Body weight (g) for male and female offspring during adolescence.
A-B: Males. C-D: Females. Rats were prenatally exposed to either lipopolysaccharide
(LPS) on G15-16, propionic acid (PPA) on G12-16, or their respective phosphate
buffered saline controls (2VEH and 5VEH). Postnatal treatment, either PPA or VEH, was
administered 2x/day every other day from P10-18. Postnatal PPA males treated prenatally
with 2VEH weighed significantly more than prenatal 2VEH-postnatal VEH males on
P45-51 (ps < 0.05). There were no significant differences in female offspring. Error bars
represent S.E.M. Refer to Table 2.2 for sample sizes.

35

2.3.1.3. Physical Milestones
There was no developmental delay and no sex differences in pups as a result of
either prenatal PPA or LPS treatment for eruption of top and bottom incisors, and pinna
detachment (Figure 2.3A-C). There was developmental delay observed in day of eye
opening in both prenatal PPA and prenatal LPS treated male and female pups (Figure
2.4). A significant Day x Prenatal drug interaction, F(12,762) = 13.0, p < 0.001, indicated
that prenatal PPA and LPS treated male and female pups were significantly different
from both 5VEH (ps < 0.01) and 2VEH treated pups (ps < 0.05) on P14, while on P15,
prenatal PPA treated male and female pups were significantly different from 5VEH and
LPS (ps < 0.05).
2.3.1.4. Reflexes
The day at which rat pups could perform a righting reflex was monitored. A sex
difference was present, F(1,147) = 6.70, p = 0.011, with males performing the reflex
significantly earlier than females, with prenatal drug treatment having no significant
effect on this reflex (Figure 2.5A). Negative geotaxis was monitored daily on P7-10 to
ensure motor reflex development (Figure 2.5B). There was no delay among treatment
groups and all animals showed improvement across days, F(3,588) = 3.66, p = 0.012.
Lastly, on P15, a free-fall righting reflex test was performed with a higher score
indicating good performance. There was a significant Sex x Prenatal drug x Postnatal
drug interaction, F(3,146) = 4.95, p = 0.003. Males receiving prenatal LPS and postnatal
PPA had significantly higher scores on the free-fall righting reflex test than males
receiving prenatal LPS and postnatal VEH, p = 0.002. Females receiving prenatal LPS
and postnatal PPA had significantly lower scores on the reflex test than females receiving
prenatal LPS and postnatal VEH (p = 0.031) and lower scores than females receiving
prenatal 2VEH and postnatal PPA (p = 0.029) or prenatal PPA and postnatal PPA (p =
0.042, Figure 2.5C).
2.3.2. Behavioural Tests in Adolescence
2.3.2.1. Open-Field Locomotor Activity
Generally, regardless of drug treatment, female offspring were more active than
male offspring for total distance traveled, F(1,100) = 8.55, p = 0.004, horizontal
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Figure 2.3. Physical developmental milestones for male and female offspring.
Pups were monitored daily and postnatal day of milestone emergence was recorded. A:
Pinna detachment, B: Top incisor eruption, and C: Bottom incisor eruption. There were
no significant effects of prenatal treatment and no sex differences. Error bars represent
S.E.M. Refer to Table 2.1 for group designations and sample sizes.
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Figure 2.4. Eye opening across postnatal days for prenatal treatment groups.
Data is collapsed across sex and postnatal treatment as there were no significant effects of
these on eye opening. On P14, both prenatal LPS (^, p < 0.05) and PPA treated animals
were delayed compared to vehicle treated controls (* p < 0.05, ** p < 0.01). On P15,
prenatal PPA treated pups continued to exhibit delayed eye opening. Error bars represent
S.E.M. Refer to Table 2.1 for group designations and sample sizes.
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Figure 2.5. Reflexes during early life for male and female offspring.
A. Righting reflex: the day at which animals could right themselves from a supine
position with all limbs outstretched. Male pups righted significantly earlier than females.
B. Negative geotaxis: on postnatal days 7-10, the time in seconds that it took animals to
rotate 180° on a 30° incline when placed head down. An effect of Day indicated that pups
completed a 180° turn more quickly across postnatal days. There were no significant
effects of sex or prenatal drug. C. Free-fall righting reflex: 3 trials occurred, with a
successful trial given a score of 1. In prenatal LPS treated pups, postnatal PPA produced
sex differences, with higher scores in postnatal PPA treated males and lower scores in
postnatal PPA treated females compared to postnatal VEH treated males and females,
respectively. Error bars represent S.E.M. Refer to Table 2.1 for group designations and
sample sizes. * p < 0.05, ** p < 0.01
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movement time, F(1,100) = 6.31, p = .014, and number of revolutions, F(1,93) = 11.86, p
= 0.001). Significant main effects of Prenatal drug were found for total distance traveled,
F(3,100) = 3.23, p = 0.026, and number of horizontal movements, F(3,100) = 4.37, p =
0.006, but not for horizontal movement time. Animals prenatally exposed to PPA or
5VEH moved a significantly greater total distance than animals in both the LPS and
2VEH control group, ps < 0.05 (Figure 2.6A, B). Further analysis showed this difference
to be present in only female offspring as prenatal PPA and 5VEH treated females were
significantly more active than prenatal LPS treated females, ps < 0.01. Animals
prenatally exposed to 5VEH performed a significantly greater number of horizontal
movements than the other 3 prenatal drug groups (PPA p = 0.040, 2VEH p = 0.002, LPS
p = 0.003), with the same effect in both male (5VEH significantly greater than 2VEH p =
0.014) and female offspring (5VEH significantly greater than 2VEH, LPS ps < 0.05,
Figure 2.6C).
There were no effects of prenatal LPS or PPA, or postnatal PPA treatment on
vertical activity measures (number of vertical movements and vertical movement time,
data not shown). For number of revolutions, the Sex x Prenatal drug x Postnatal drug
interaction was nearly significant, F(3,93) = 2.68, p = 0.051. Further analysis showed
that a double hit of prenatal and postnatal PPA increased the number of revolutions made
in the female offspring, but not in the male offspring (Figure 2.6D). Female offspring
exposed to prenatal and postnatal PPA displayed significantly more revolutions than their
male counterparts (p = 0.001), prenatal PPA-postnatal VEH treated females (p = 0.046),
and female offspring exposed to prenatal LPS or 2VEH and postnatal PPA (ps < 0.05).
Overall, prenatal PPA, prenatal LPS, and postnatal PPA alone did not produce
hyper- or hypo-activity in male and female adolescent offspring. Prenatal PPA and
postnatal PPA combined significantly increased repetitive behaviour (number of
revolution) in female, not male offspring.
2.3.2.2. Open-Field Thigmotaxis
There was a significant main effect of Prenatal drug, F(3,100) = 4.83, p = 0.004,
for percent time spent in the centre (Figure 2.7A). Prenatal PPA treated animals spent
significantly less time in the centre of the open-field compared to prenatal 5VEH treated
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Figure 2.6. Locomotor activity in a novel open-field (P42) in male and female offspring.
Adolescent females moved significantly more than males. Total distance traveled (cm):
A: Sex x Prenatal treatment and B: Prenatal treatment. Prenatal PPA and 5VEH treated
animals moved significantly more than prenatal LPS and 2VEH treated animals. C:
Number of horizontal movements. An effect of prenatal treatment showed animals in the
prenatal 5VEH group made significantly more horizontal movements than the other 3
prenatal treatment groups. D: Number of revolutions. Females made significantly more
revolutions than males. A double hit of prenatal PPA and postnatal PPA produced
significantly more revolutions in female offspring compared to prenatal PPA alone in
females and a double hit of PPA in males. Error bars represent S.E.M. Refer to Table 2.2
for group designations and sample sizes. * p < .05, ** p < .01
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controls, p = 0.005. Prenatal 2VEH and LPS treated animals also spent significantly less
time in the centre than animals treated with 5VEH (2VEH p = 0.023, LPS p = 0.001).
There were no significant effects of drug on the number of entries into the centre or
perimeter of the open-field and postnatal PPA as compared to postnatal VEH had no
significant effect on percent time in the centre or perimeter of the open-field (Figure
2.7B).
Locomotor activity measures were corrected for the amount of time spent in the
perimeter or centre of the open-field. Prenatal LPS, prenatal PPA, and postnatal PPA did
not significantly affect locomotor activity in the perimeter of the open-field on any
horizontal or vertical activity measures. Females traveled significantly greater total
distances, Sex F(1,100) = 11.53, p = 0.001, and spent more time moving horizontally
than males, Sex F(1,100) = 8.41, p = 0.005 (data not shown).
Postnatal PPA and prenatal LPS also did not affect central locomotor activity.
However, prenatal PPA resulted in increased activity in the centre of the open-field.
There were significant main effects of Sex, F(1,100) = 5.82, p = 0.018, and Prenatal drug,
F(3,100) = 5.14, p = 0.002, for total distance traveled in the centre (Figure 2.7C) and a
significant main effect of Prenatal drug, F(3,100) = 2.82, p = 0.043, for horizontal
movement time in the centre (data not shown). Animals in the prenatal PPA group
traveled significantly greater total distances than all other prenatal groups (5VEH p <
0.001, LPS p = 0.006, 2VEH p = 0.008). This effect was present in both females (prenatal
PPA significantly greater than other 3 groups, ps < 0.01) and in males (prenatal PPA
significantly greater than 5VEH, p = 0.021). For horizontal movement time, prenatal PPA
treated animals spent significantly more time moving in the centre than 5VEH treated
animals, p = 0.005.
While in the centre of the open-field, females generally performed more vertical
movements, Sex F(1,93) = 6.56, p = 0.012, and spent more time engaged in rearing than
males, Sex F(1,100) = 4.48, p = 0.037. A significant Sex x Prenatal drug interaction for
number of vertical movements in the centre of the open-field, F(3,93) = 2.89, p = 0.040,
indicated that females prenatally exposed to PPA performed a significantly greater
number of vertical movements than prenatal PPA treated males, p = 0.001 (Figure 2.7D).
No significant effects of prenatal drugs (LPS or PPA) were found for vertical time.
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Figure 2.7. Thigmotaxis measures in a novel open-field (P42) in male and female
offspring.
Activity measures were time corrected. Females moved significantly more than males. A:
Percent time in the centre of the open-field. Animals in the prenatal PPA treated group
spent significantly less time in the centre of the open field than the prenatal 5VEH group.
B: Number of entries into the centre. There were no significant differences in entries into
the centre. C: Total distance traveled (cm/s). Male and female offspring in the prenatal
PPA treated group traveled significantly greater distances than the 5VEH treated control
group. D: Number of vertical movements. Prenatal PPA treated female offspring reared
significantly more than prenatal PPA treated male offspring. Error bars represent S.E.M.
Refer to Table 2.2 for group designations and sample sizes. * p < .05, ** p < .01
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Overall, prenatal LPS and postnatal PPA did not significantly alter time spent, or
locomotor activity, in the perimeter or centre of the open-field. However, prenatal PPA
significantly increased locomotor activity in the centre of the open-field in both males
and females.
2.3.2.3. Elevated Plus Maze
The number of entries into the closed arm was used as a measure of locomotion.
There were no significant differences among groups in closed arm entries (Figure 2.8A).
Number of entries into the open arm, percent time spent in the open arm, and closed arm
time were used as traditional measures of anxiety-like behaviour.
For number of entries into the open arm, there was a Prenatal drug x Postnatal
drug interaction, F(3,92) = 2.99, p = 0.035. Postnatal PPA treated animals in the prenatal
5VEH group entered the open arm significantly fewer times than postnatal VEH animals
(p = 0.01). A significant Sex x Prenatal drug interaction for both open arm entries,
F(3,92) = 9.45, p < 0.001, and percent time in the open arm, F(3,99) = 7.14, p < 0.001,
showed there were no differences in open arm entries among male offspring. Female
offspring prenatally exposed to PPA entered the open arm significantly less often (p =
0.001) and spent significantly less time in the open arm than prenatal 5VEH treated
female offspring (p < 0.001, Figure 2.8B, C). Prenatal LPS and 2VEH treated females
were also significantly less than prenatal 5VEH treated females for open arm entries and
percent time in the open arm (ps < 0.001). The significant Sex x Prenatal drug interaction,
F(3,92) = 4.10, p = 0.009, for time spent in the closed arm showed that female offspring
in the prenatal 5VEH group spent significantly less time in the closed arm than female
offspring in the other 3 prenatal groups (ps < 0.01, Figure 2.8D). Postnatal PPA treated
animals also spent significantly more time in the closed arm than postnatal VEH treated
animals, Postnatal drug F(1,92) = 6.74, p = 0.011, but this was only in female offspring
(p = 0.037).
In summary, females in the prenatal PPA group made significantly less open arm
entries, and spent less percent time in the open arm with more time in the closed arm than
controls. Postnatal PPA significantly increased closed arm time in female offspring.
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Figure 2.8. Elevated plus maze (P40) for male and female offspring.
A: Number of closed arm entries was not significant. B: Number of open arm entries, C:
Percent time in the open arm, D: Time in closed arm. Female offspring in the prenatal
PPA group made less open arm entries, spent less time in the open arm, and spent more
time in the closed arm than the prenatal 5VEH group. Error bars represent S.E.M. Refer
to Table 2.2 for group designations and sample sizes. * p < 0.05, ** p < 0.01, *** p <
0.001
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2.4. Discussion
Until relatively recently, limited attention has been given to possible
developmental effects of microbiome associated, GI metabolic products in rodents.
Likewise, investigations of the effects of prenatal and postnatal immune activation with
LPS and poly I:C have been mostly limited to adult male rodents. The present study
investigated the effects of prenatal PPA and prenatal LPS in the emergence of postnatal
developmental milestones, locomotor activity and on anxiety-like behaviour in both male
and female adolescent offspring. Additionally, a PPA regimen in the second week of life
was used to evaluate if a subsequent postnatal insult would exacerbate any behavioural
effects of prenatal treatment.
Prenatal LPS and PPA treatment resulted in developmental delays in male and
female offspring, suggesting altered neurodevelopmental effects. Prenatal PPA alone did
not influence open-field activity, but as expected, prenatal PPA produced increased
anxiety-like behaviour as evidenced by decreased time spent in the centre of the openfield in male and female adolescent rats, and less time on the open arm of the elevated
plus maze (EPM) in females. Prenatal LPS did not alter behaviour in the open-field and
EPM. Postnatal PPA alone did not alter open-field activity, yet increased anxiety-like
behaviour in the EPM. Evidence for the double hit hypothesis was present in female
adolescent rats, with the combination of PPA treatments increasing repetitive behaviour.
As a whole, the present results provide evidence that prenatal LPS or PPA and postnatal
PPA can alter neurodevelopmental processes and that these changes manifest as sex- and
test-specific alterations in activity and anxiety-like behaviour in adolescent rats.
2.4.1. Prenatal and postnatal treatments produce developmental delay
Prenatal and postnatal treatments influenced body weight and developmental
milestones. Body weight in male and female offspring was affected slightly by postnatal
PPA treatment administered in the second week of life. Male pups were heavier and
female pups were lighter than control pups, with the effects in males reaching
significance across days. PPA administered in the first week of life and postnatal VPA in
prior studies had no effect on body weight (Brusque et al., 1999; Reynolds et al., 2012).
However, while postnatal LPS has been demonstrated to not influence body weight in the
first 3 weeks of life, there is some evidence of increasing body weight in males
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throughout adolescence (Iwasa et al., 2010; Spencer et al., 2007). There were no
differences in females with postnatal PPA and differences in males only in the prenatal
2VEH group at adolescence, suggesting minimal long-lasting effects on body weight.
Motor reflexes and development also developed normally in early life, consistent
with previous studies in rats receiving LPS and VPA (Baharnoori et al., 2010; Schneider
and Przewlocki, 2005). In female offspring, there was a deficit in the ability to right midair on P15 in animals receiving a combination of prenatal LPS and postnatal PPA
compared to prenatal vehicle treated controls. Prenatal VPA impaired free-fall righting in
male and female offspring (Wagner et al., 2006), while daily postnatal administration of
PPA impaired free-fall righting in male offspring (Brusque et al., 1999). However, in
males, prenatal LPS males receiving postnatal PPA were found to have higher righting
ability scores compared to prenatal LPS-postnatal VEH treated males. These findings
suggest that changes in activity in prenatal LPS and PPA treated adolescents are not due
to developmental impairment in motor functions, but rather are associated with
developmental changes in underlying neurobiological processes.
Physical developmental milestones monitored were normal in prenatal PPA and
LPS treated pups compared to vehicle controls, with the exception of eye opening, which
was delayed in both prenatal PPA and LPS treated male and female pups. These results
are consistent with previous studies showing VPA delayed eye opening (Roullet et al.,
2010; Schneider and Przewlocki, 2005). In contrast, prenatal LPS on G15-16 at a higher
dose than this study found no delay in eye opening (Baharnoori et al., 2010), which may
suggest that Long-Evans rats are more susceptible to developmental delay with prenatal
LPS than Sprague-Dawley rats. Eye opening has been shown to be important for
initiating glutamatergic synapse maturation (Zhao et al., 2013). As such, prenatal LPS
and PPA treatment and postnatal PPA appear to have the capacity to affect some
developmental processes.
2.4.2. Prenatal PPA and postnatal PPA combined produces repetitive behaviour in
female offspring
Overall, female adolescent rats displayed greater levels of basal locomotor
activity than males, consistent with what is seen in adults (Lynn and Brown, 2009; Lynn
and Brown, 2010). Previously, central administration of PPA directly into the brain
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ventricles of adult males increased locomotion and repetitive behaviour (MacFabe et al.,
2007; Thomas et al., 2012). While these acute administrations are not directly
comparable to prenatal effects, they do point to possible direct locomotory effects with
prenatal PPA. However, prenatal PPA or postnatal PPA alone did not affect locomotor
activity. In fact, a ‘double hit’ of PPA in female offspring was required to produce an
increase in repetitive movement, as measured by number of revolutions. This is similar to
the results of Schneider et al. (2008) who reported a single injection of prenatal VPA
increased duration and number of stereotypic movements in adult female rats, but not
male rats.
Prenatal VPA has been shown to produce hyperactivity in male and female
juvenile rats (P22-28) and adolescent male rats in an open-field (Dendrinos et al., 2011;
Schneider and Przewlocki, 2005). The present findings suggest that PPA at the present
dosage may not be as effective as VPA and/or exert its effects through different
mechanisms (Dawson, 1991). MIA offspring challenged with dopamine and NMDA
drugs show increased locomotor activity compared to MIA controls challenged with the
drugs (Fortier et al., 2004; Howland et al., 2012). It is possible that PPA also affected
dopamine neurotransmission (DeCastro et al., 2005; Rorig et al., 1996), and that changes
are subtle and might only appear if animals were challenged with psychomimetic drugs at
the time of testing.
General activity in a novel open-field was greater in prenatal PPA and 5VEH
treated offspring compared to LPS and 2VEH treated offspring. Receiving five injections
may have induced a mild stress response and been enough of a stressor to affect
development. Prenatally stressed rats have been shown to be hyperactive in a novel openfield, as well as displaying anxiety-like behaviour (Fride and Weinstock, 1988; Wilson et
al., 2013). Repeated injections can alter baseline levels of plasma corticosterone (Drude
et al., 2011; Ryabinin et al., 1999) and prenatal stress can compromise the placental
barrier, exposing developing animals to corticosterone (O'Donnell et al., 2009). This may
have led to greater activity in a potentially stressful situation, in this case, a novel openfield.
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2.4.3. Prenatal LPS did not influence locomotor activity and anxiety-like behaviour
General activity in an open-field does not seem to be altered by MIA alone in
adolescent or adult offspring, as observed in this and prior studies (Fortier et al., 2004;
Howland et al., 2012; Lin et al., 2012; Vorhees et al., 2012). This does not necessarily
indicate that there are no developmental changes in neural functioning. For example,
Fortier et al. (2004) found no change in open-field activity with a low dose of prenatal
LPS until adult rats were challenged with amphetamine. Alternatively, the open-field
used in this study may have been too small to detect aversiveness to the centre of the
open-field in prenatal LPS-treated rats. In a study with a larger novel open-field, prenatal
LPS induced decreases in locomotor activity and time spent in the centre (Lin et al.,
2012).
The low dose of LPS (50 g/kg) administered during mid-late gestation (G15-16)
may help explain why there were no effects of prenatal LPS on anxiety measures in the
open-field and EPM. Increased anxiety-like behaviour in the EPM was observed in
adolescent male rats prenatally exposed to LPS on G16 or G17 at higher doses (100 and
150 g/kg), and in adult mice offspring exposed to a similar dose of LPS as this study,
but earlier prenatally (G10), or postnatally (Enayati et al., 2012; Lin et al., 2012; MajidiZolbanin et al., 2013). While prenatal LPS produced developmental delay in rats, it was
not sufficient to alter anxiety-like behaviour.
2.4.4. Prenatal PPA increased anxiety-like behaviour in the open-field
When the open field was divided into centre and perimeter zones, prenatal PPA
treatment increased anxiety-like behaviour in both male and female offspring. Reduced
time in the centre is indicative of increased anxiety, as the open space acts as an aversive
space. Adolescent males and females prenatally exposed to PPA were also hyper-active
when in the centre of the open-field, which may suggest a level of aversiveness. Adult
rats fed a carbohydrate-rich diet exhibited anxiety and elevated levels of SCFAs in the
gut (Hanstock et al., 2004) while previous research with MIA and VPA report decreased
time in the centre of an open-field in adolescent male and female offspring (Lin et al.,
2012; Smith et al., 2007; Vorhees, 1987). Additionally, infection of germ-free mice with
a Gram-negative enteric pathogen (Campylobacter jejuni) increased anxiety behaviour
and was associated with increased early gene expression in brain regions implicated in
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anxiety (Goehler et al., 2008; Lyte et al., 2006). However PPA, unlike LPS and C. jejuni,
is not a pathogen and may not alter developmental processes in the same way. It is
possible that similar immune processes are activated (e.g., cytokine release) as central
PPA induces an innate neuroinflammatory response in the brain (MacFabe et al., 2007);
however, it remains to be seen if PPA in development alters immune function in rat
offspring.
2.4.5. Prenatal and postnatal PPA increased anxiety-like behaviour in the EPM
There were sexually dimorphic effects of prenatal and postnatal PPA treatment,
with female rats displaying increased anxiety-like behaviour. Compared to 5VEH treated
control females, time in the open arm and open arm entries were decreased in prenatal
PPA treated females and closed arm time was increased in prenatal PPA and postnatal
PPA treated females. An increase in anxiety is consistent with previous reports of
prenatal VPA and enteric infection producing anxiety-like behaviour in male and female
adult rat offspring (Lyte et al., 1998; Markram et al., 2008; Schneider et al., 2008).
A sex difference was present in the 5VEH control group, with males exhibiting
similar levels of behaviour as prenatal PPA treated males and females, suggesting anxiety
in these control males. Brief daily periods of maternal stress resulted in increased anxiety
in male adolescent rats, but not females (Muhammad and Kolb, 2011). To prevent an
effect of prenatal PPA in males from being significant, mild stress associated with the
control injections may have increased exposure to corticosterone and altered
developmental processes in males. Studies of prenatal stress have shown sex differences
in neurogenesis, decreased levels of testosterone and increased levels of corticosterone in
offspring that may account for alterations in behaviour (reviewed in Weinstock, 2011).
Similar to prenatal 5VEH males, both males and females treated with LPS and
2VEH displayed low levels of activity on the EPM. There may have been a ceiling effect
in the current study that prevented an effect of LPS from being evident. It appears that
this effect may be specific to these animals as behavioural testing occurred in a paired
fashion (2VEH and LPS animals tested on the same day, and 5VEH and PPA animals
tested together), and prenatal 5VEH treated females performed as expected. It is unclear
why 2VEH and LPS treated animals produced such low levels of maze exploration. It has
been shown that exposure to additional stressors has been required before increased
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anxiety-like behaviour on the EPM was observed in rats treated with postnatal LPS
(Breivik, 2002; Walker et al., 2009). Additionally, EPM results are sensitive to multiple
environmental factors including prior housing condition, illumination levels, and prior
handling (reviewed in Carobrez and Bertoglio, 2005). Some aspect of the current EPM
set-up may have induced a stressful state that led to decreased levels of exploration in the
maze. Future investigations under different conditions may provide insight on this issue
and how it relates to results of previous studies.
2.4.6. LPS and PPA have the potential to alter neurodevelopmental processes
An imbalance between excitation and inhibition in the brain has been implicated
in autism and anxiety, with changes in GABA and possibly serotonin suggested to be
critical. Modifications in GABAergic systems have been reported in various brain regions
of patients with ASD (Fatemi et al., 2002; Oblak et al., 2010) and these systems may be
vulnerable to environmental agents during development.
SCFAs and VPA can cross the placenta via monocarboxylate transporters and
gain access to the developing fetus (Nagai et al., 2010; Ushigome et al., 2001). PPA and
VPA can act as histone deacetylase inhibitors and induce changes in gene expression
(D'Souza et al., 2009; Phiel et al., 2001) with preliminary results demonstrating that
central administration of PPA can alter gene expression in ASD associated genes
(unpublished observations). Oral PPA during gestation and early life depleted whole
brain GABA, serotonin, and dopamine and increased IL-6 in young rat brains (El-Ansary
et al., 2011). Further investigation into the mechanisms associated with PPA-induced
alterations in development and behaviour is needed.
While no behavioural effects of LPS were found in the current study, acute and
chronic LPS during gestation induces a proinflammatory response and alters the placental
barrier, which may allow external agents and/or cytokines to gain access to the fetus
(Bloise et al., 2013; Shi et al., 2005). Increases in proinflammatory cytokines, and
changes in gene expression and GABAergic neurons have been found following prenatal
LPS treatment (Garbett et al., 2012; Gayle et al., 2004; Nouel et al., 2012).
2.4.7. Conclusion
In summary, these results are the first to demonstrate that prenatal PPA, and one
of a few to demonstrate that postnatal PPA and a low dose of LPS, alters developmental
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processes and subsequent behaviour in male and female adolescent rats, resembling
alterations observed in ASD and previous animal models. Prenatal LPS and prenatal PPA
produced delay in eye opening and prenatal and postnatal PPA increased anxiety-like
behaviour in both male and female offspring, with a greater effect observed in female
offspring. Developmental delay and altered temperament are observed in children with
ASD, as reduced communication and motor skills or inappropriate emotional responses
(e.g., passiveness) are observed (Mitchell et al., 2011; Zwaigenbaum et al., 2005) and
anxiety disorders were the most common psychiatric conditions reported in ASD
populations (Skokauskas and Gallagher, 2010). There was no male bias in PPA and LPS
induced alterations in behaviour, unlike the male predominance seen in ASD. A more
balanced male to female ratio and the presence of gastrointestinal abnormalities was
observed in children with ASD and mitochondrial disease (MD) (Rossignol and Frye,
2012). It is possible that environmental insults contribute differently to the sex ratio
observed in ASD. Additionally, evidence suggests that females with ASD display more
severe behavioural symptoms than males and are likely to show more repetitive interests
(Fombonne, 2009; Mandy et al., 2012; Russell et al., 2011). The current results support
this with a female sensitivity to PPA effects on repetitive behaviour and anxiety. These
results provide evidence that by-products of enteric bacteria metabolism can alter
development and behaviour in rats resembling that of ASD. Repeated infection or
immune insult throughout gestation and early life may induce intestinal inflammation and
alter the composition of the gut microbiome. Subsequent production of metabolic
products, such as LPS and PPA, has the potential to adversely alter neurodevelopment in
susceptible populations.
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Chapter 3
Prenatal exposure to lipopolysaccharide and pre- and postnatal exposure to
propionic acid, alters acoustic startle response and prepulse inhibition in male and
female adolescent rats
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3.0. Summary
Potential environmental risk factors for autism spectrum disorders (ASD) include
viral/bacterial infection and an altered microbiome composition. The present study
investigated whether administration of immune and gastrointestinal factors during
gestation and early life altered startle response and prepulse inhibition in adolescent
offspring using lipopolysaccharide (LPS), a bacterial mimetic, and propionic acid (PPA),
a short chain fatty acid and enteric metabolic bacterial product. Pregnant Long-Evans rats
were injected once a day with PPA (500 mg/kg SC) on gestation days G12-16, LPS (50
g/kg SC) on G15-16, or vehicle control on G12-16 or G15-16. Male and female
offspring were injected with PPA (500 mg/kg SC) or vehicle twice a day, every second
day from postnatal days 10-18. Acoustic startle response and prepulse inhibition was
measured on postnatal days 45, 47, 49, and 51. Prenatal and postnatal treatments altered
startle response characteristics in a sex-specific manner. Prenatal LPS treatment produced
hypersensitivity to acoustic startle in males, but not females and did not alter prepulse
inhibition. Subtle alterations in startle responses, which disappeared with repeated trials,
occurred with prenatal PPA and postnatal PPA treatment in both male and female
offspring. Prenatal PPA treatment decreased prepulse inhibition in females, but not
males. Females receiving a double hit of PPA (prenatal and postnatal) showed
sensitization to acoustic startle, providing evidence for the double hit hypothesis. The
current study provides support for the hypothesis that immune activation and metabolic
products of enteric bacteria can alter development and behaviour in ways that resemble
sensory abnormalities observed in ASD.
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3.1. Introduction
The prevalence of autism spectrum disorders (ASD) has increased to
approximately 1 in 88 children (Autism and Developmental Disabilities Monitoring
Network Surveillance Year 2008 Principal Investigators, 2012). ASD encompasses a
wide range of behavioural symptoms, including impairments in communication and
social behaviour, and the presence of stereotyped movements and repetitive behaviour
(DiCicco-Bloom et al., 2006). In the DSM-5, sensory aspects have been incorporated into
the repetitive and restrictive behaviour domain, as both hyper- and hypo-sensitivities to
stimuli across multiple modalities are reported (Leekam et al., 2007; Marco et al, 2011).
Both genetic and environmental factors contribute to the development of ASD. A number
of genes have been implicated as well as de novo copy number variations (Cook and
Scherer, 2008; Geschwind, 2011), with heritability estimates of 90%. However,
concordance rates among monozygotic twins is reported to range from 50-90% (Bailey et
al., 1995; Hallmayer et al., 2011), leaving an important role for environmental risk factors
to act on underlying genetic susceptibilities (Herbert, 2010).
Immune dysfunction may increase the risk for ASD as alterations in the adaptive
and innate cellular immune responses have been observed in children with ASD (see
Onore et al., 2012 for review). Viral infection in the first trimester and bacterial infection
in the second trimester have been associated with development of ASD (Atladottir et al.,
2010). During an immune insult, the release of proinflammatory cytokines, which act
both peripherally and centrally, result in a range of behavioural and physiological
responses termed sickness behaviours. This release of cytokines during critical periods
may have adverse consequences for neurodevelopmental processes, such as cell
differentiation, migration, and synaptogenesis (Bilbo and Schwarz, 2012; Deverman and
Patterson, 2009).
There has been an increasing interest in the role of host gut microbial populations,
or microbiome, in communicating with the central nervous system and influencing
gastrointestinal (GI), immune, and neuropsychiatric health (Cryan and Dinan, 2012;
Nicholson et al., 2012). Imbalances in the composition of the microbiome and the
immune sequelae may also contribute to the development and/or maintenance of ASD in
children. Support for this comes from findings of abnormal levels of bacteria flora,
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including augmented Clostridia, Bacteroidetes, and Desulfovibrio subtypes, in the GI
tract of autistic children (Finegold et al., 2002; Finegold et al., 2012; Parracho et al.,
2005). As these anaerobic bacteria are antibiotic-resistant, repeated early infections in
postnatal life treated with antibiotics may provide an enteric environment that promotes
the overgrowth of these bacteria and the propensity for intestinal inflammation and
associated neuroimmune and neurohormonal changes (Cho et al., 2012; Finegold et al.,
2012).
Metabolic products of these bacteria include short chain fatty acids (SCFA, from
carbohydrate metabolism) (Finegold et al., 2010), which are able to enter circulation and
may alter metabolic and immune function and/or exacerbate ASD behaviours. Indeed,
propionic acidemia, a neurodevelopmental metabolic disorder characterized by elevated
levels of the SCFA, propionic acid (PPA), clinically resembles some aspects of autism
(Feliz et al., 2003) and a case study of comorbidity of propionic acidemia and ASD has
been presented (Al-Owain et al., 2013). Our laboratory has proposed that PPA, produced
by enteric bacteria, may be a potential environmental factor in the development of ASD.
Central administration of PPA in adult male rats has produced a number of brain and
behavioural changes including hyperactivity and decreased social behaviour consistent
with ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe et al., 2011; MacFabe,
2012; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2012) and has predictive
value in many metabolic alterations in a subset of ASD patients (Frye et al., 2013).
Maternal immune activation (MIA) in rodents is used to investigate the role of the
immune system in ASD. An inflammatory response is induced using a variety of agents,
including influenza and polyinosinic:polycytidylic acid (poly I:C- a viral mimetic).
Lipopolysaccharide (LPS, a bacterial mimetic) is the major component of the cell wall of
Gram-negative bacteria and is also a by-product of many enteric bacteria metabolism.
Offspring of dams treated with these immune agents display behavioural deficits in
exploratory behaviour and social interaction (Fortier et al., 2007; Romero et al., 2010; Shi
et al., 2003; Smith et al., 2007). Valproic acid (VPA), an epilepsy treatment that increases
the risk of ASD, shares pharmacological properties with PPA (Brass, 1992; Coulter,
1991), and is also widely used in animal studies. Prenatal administration of VPA
produced developmental delay and behavioural deficits (reviewed in Roullet et al., 2013).
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Brusque et al. (1999) administered daily PPA throughout postnatal life (days 6-28 of life)
and reported developmental delay with mild behavioural deficits. To date, there are no
published studies on the effects of prenatal PPA and one study (Brusque et al., 1999) on
the effects of postnatal PPA administration on behaviour in offspring.
Sensory abnormalities reported in children and adults with autism vary in
modalities affected and severity. In both self-reports and parental reports, over 90% of
those with autism report unusual responses to sensory stimuli (Crane et al., 2009; Leekam
et al., 2007). Both hyper-responding (more than typical) and hypo-responding (below
normal response) to taste/smell, tactile, visual, and auditory stimuli have been observed,
and there is evidence of abnormal sensory integration (Baranek et al., 2007; Iarocci and
McDonald, 2006; Leekam et al., 2007; Rogers et al., 2003). Difficulties with habituation
to sensory stimuli (decreased responding to repeated stimuli over time) have also been
observed (Barry and James, 1988; Ornitz et al., 1993), but are not always present in
patients (Baranek et al., 2007; Rogers and Ozonoff, 2005).
In animal models, the acoustic startle response (ASR) is a commonly used
measure of sensory responsiveness. The ASR can be modulated in a number of ways,
including with a low intensity prepulse and with habituation. Habituation is the reduction
in startle response with repeated presentation of the stimulus. Prepulse inhibition refers to
a decrease in acoustic startle response level that occurs when the startle stimulus is
preceded 30-500 ms by a non-startling stimulus (prepulse). This inhibition effect is
presumed to be due to sensory filtering to allow prepulse processing (Koch, 1999).
As ASD are present in childhood and are more prevalent in males, it is important
to conduct animal studies on younger animals and investigate both males and females for
possible sex differences. Although more attention has been recently focused on sex
differences in adults, the majority of animal studies have used male adults (Boksa, 2010),
and information on adolescents is still lacking. Also, few studies assess ASR, focusing on
other behavioural tests, though prepulse inhibition is more frequently included in
behavioural test batteries. While repeated treatment with LPS throughout gestation has
been shown to decrease prepulse inhibition in adolescent male and female rats (Romero
et al., 2010), there are no reports, to our knowledge, of the effects of prenatal LPS
administered at specific gestational time points on ASR, habituation, or prepulse
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inhibition in adolescent offspring. Previous MIA research has obtained decreases in
prepulse inhibition in adult male and female (Basta-Kaim et al., 2011; Howland et al.,
2012) and adolescent male offspring (Wolff and Bilkey, 2010). Prenatal exposure to other
toxins, such as valproic acid (VPA), have resulted in mixed ASR results and decreased
prepulse inhibition in adult male and female rats and adolescent males (Markram et al.,
2008; Schneider and Przewlocki, 2005; Vorhees, 1987).
The present study investigated the effects of prenatal treatment with LPS or PPA,
on ASR, habituation, and prepulse inhibition in adolescent male and female offspring.
Additionally, a second ‘hit’ of PPA, in the second postnatal week, was given to act as an
early life insult to mimic postnatal production of SCFA from the developing gut
microbiota (Midtvedt and Midtvedt, 1992; Nafday et al., 2005). This double hit
hypothesis has been proposed for schizophrenia, where genetic predisposition leaves
individuals vulnerable to an environmental trigger later in life that results in
manifestation of the disorder (Bayer et al., 1999). The “double hit” approach has also
been applied to animal models of immune activation using two environmental insults.
Immune activation early in life may confer susceptibility to disease or psychopathology
in adulthood (Giovanoli et al., 2013; Tenk et al., 2008; Walker et al., 2009). Genetics
may also confer susceptibility to prenatal or postnatal environmental insults in ASD, or,
more than one insult may be required, as in repeated infections in early life. Immune
responses can alter the composition of the microbiome of the gastrointestinal tract
(Bartlett and Gerding, 2008; Bennet et al., 2002). It is thus possible that prenatal
treatment with LPS or PPA may leave offspring vulnerable to the effects of postnatal
PPA exposure. To date, this approach has not been used in previous animal models of
ASD. Previous animal models of ASD have primarily focused on adult offspring, with
few investigations of sex differences in adolescent male and female offspring.
The present study specifically compared the effects of prenatal exposure to LPS
and/or PPA, and postnatal exposure to PPA in adolescent male and female rats. Thus,
combined treatments of prenatal LPS with postnatal PPA and prenatal PPA with postnatal
PPA are considered. These unique combinations of prenatal and postnatal treatment
assess the presence of exacerbated behavioural effects compared to treatments alone. It
was hypothesized that prenatal PPA would alter the acoustic startle response and that
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both prenatal PPA and LPS exposure would result in decreased prepulse inhibition in
adolescent offspring. If effects on behaviour were found, postnatal PPA treatment was
expected to exacerbate behaviour.
3.2. Method
3.2.1. Animals
The animals used in this experiment are the same animals from Chapter 2, with
behavioural testing following the behaviours measured in Chapter 2. Twelve primiparous
female Long-Evans rats weighing between 270-310 g were mated with adult male LongEvans rats (375-550 g, Charles River, Canada) for a total of 12 litters. Females were
paired overnight with a male the night before behavioural estrus. Sperm present on a
vaginal smear (hematoxylin & eosin stain) the morning after pairing indicated successful
mating and this was designated gestational day 0 (G0). Dams were housed individually in
standard polypropylene cages (45 x 22 x 20 cm) with ad libitum access to both food
(ProLab RMH 3000) and water. A 12:12 h light:dark cycle (lights on at 0700 h) was
maintained in a temperature controlled colony room (21 ± 2°C). Litters were born on G22
(designated as postnatal day (P) 0), toe-clipped for identification, and were weaned at
P21 (M = 14.17 pups, SD = 2.41). On P21, pups were weaned and randomly culled to a
maximum of 10 animals per litter (5 males, 5 females). Weaned rats were housed in
same-sex, same-postnatal drug groups of 2 or 3 in standard polypropylene cages under
the same conditions as the dams. All behavioural testing took place during the light phase
and body weight was monitored during testing. Procedures were approved by the
University of Western Ontario Animal Use Subcommittee and were in accordance with
the Canadian Council of Animal Care (CCAC) guidelines.
3.2.2. Prenatal LPS and PPA administration
Sodium propionate (PPA, P1880, Sigma Chemical, St. Louis, MO, USA) was
dissolved in 0.1 M phosphate buffered saline and administered at a dose of 500 mg/kg
subcutaneously (SC, pH corrected to 7.4 with concentrated HCl) once a day on G12-16
for a total of 5 injections. Injections started on G12 to mimic the VPA and MIA models
of ASD (Schneider and Przewlocki, 2005); multiple injections were administered given
the short half-life of PPA (20 min, Brusque et al., 1999). Lipopolysaccharide (LPS from
E. coli serotype 0111:B4, L2630, Sigma Chemical, St. Louis, MO, USA) was dissolved
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in 0.1 M phosphate buffered saline and administered SC at a dose of 50 g/kg on G15
and G16. Administration at this time has been shown to alter adult prepulse inhibition in
models of maternal immune activation (Fortier et al., 2007). An equivalent volume of
phosphate buffered saline was injected SC as a vehicle control (2 mL/kg) to yield two
control groups, either on G15 and G16 (2VEH) or on G12-16 (5VEH). All maternal
injections were administered between the shoulder blades.
3.2.3. Postnatal PPA administration
As synaptogenesis occurs during the first 3 weeks of postnatal life in rats (Rice
and Barone, 2000), male and female pups were injected twice a day SC with either PPA
(500 mg/kg, pH = 7.4) or equivalent volumes of phosphate buffered saline vehicle (VEH,
5mL/kg) on P10, 12, 14, 16, and 18 to correspond with an environmental insult in early
human life. Approximately half of each litter was injected with postnatal PPA, the rest
with VEH. Injections took place at 0930 h (between the shoulder blades) and 1530 h
(between the haunches).
3.2.4. Experimental procedure – Acoustic startle and prepulse inhibition (PPI)
Behavioural testing occurred in late adolescence on P45, 47, 49, and 51.
Additional behavioural testing took place prior to startle testing (Chapter 2). A summary
of the treatment groups is provided in Table 3.1. The prenatal and postnatal injection
schedule yielded the following treatment combinations for each sex: Vehicle only
(prenatal 2VEH or 5VEH with postnatal VEH); Prenatal treatment alone (prenatal LPS or
PPA with postnatal VEH); Postnatal PPA alone (prenatal 2VEH or 5VEH with postnatal
PPA); Prenatal and Postnatal treatment combined (prenatal LPS or PPA with postnatal
PPA).
Acoustic startle response and prepulse inhibition (PPI) testing was conducted in 3
separate startle chambers (SRLAB, San Diego Instruments, San Diego, CA). Each
chamber consisted of a cylindrical, clear acrylic rat enclosure (10.2 cm outside diameter)
mounted on an acrylic platform. The platform sat on a piezoelectric accelerometer which
transduced the force of animal movement. This was placed inside a ventilated, sound
attenuating box containing a mounted fluorescent light and a speaker which emitted the
background noise, prepulse and acoustic startle stimuli. Data were recorded for 100 ms

69

Table 3.1. Summary of treatment groups

Prenatal treatment
LPS
5VEH
6
6

(M)

2VEH
6

PPA
6

24

(F)

6

6

6

6

24

(M)

8

8

9

9

34

(F)

8

9

9

9

35

28

29

30

30

117

VEH
Postnatal
treatment
PPA

Total

Note: Numbers in the table represent number of animals per group for males (M) and
females (F). There were 3 litters in each of the 4 prenatal groups (2VEH, 5VEH: 2 or 5
injections of phosphate buffered saline vehicle on G15-16 or G12-16, respectively; LPS:
Lipopolysaccharide, 50 ug/kg on G15-16; PPA: Propionic acid, 500 mg/kg on G12-16).
Postnatal treatment during the second week of rat pups’ life consisted of phosphate
buffered saline vehicle (VEH) or propionic acid (PPA). A maximum of 5 males and 5
females (3 postnatal PPA, 2 postnatal VEH for each sex) per litter were included in
behavioural testing. Testing took place from P45-51.
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immediately following the onset of the acoustic startle stimulus. The magnitude of the
first peak in the startle response from stimulus onset was taken as the measure of the
acoustic startle response. Four testing sessions in the startle apparatus took place, one on
each of P45, 47, 49, and 51.
In a testing session, which lasted approximately 22 min, a 5 min acclimation
period with background noise (70 dB) was followed by a 17 min (67 trials) testing
session in which the 70 dB background noise was maintained. Eleven trial types were
used in the testing session; startle-alone trials (consisting of a 115 dB burst of white noise
stimulation lasting 40 ms in duration), six different prepulse inhibition trial types
(prepulses 3, 6 or 12 dB louder than the 70 dB background noise (73, 76 and 82 dB,
respectively), each consisting of a 20 ms burst of white noise presented with an onset
either 120 ms prior to the startle pulse (100 ms inter-stimulus interval, ISI) or 80 ms prior
to the startle pulse (60 ms ISI)), and four control trial types (no pulse, 73, 76, or 82 dB
prepulse only).
The first 10 trials were startle-alone trials which served to reduce the amount of
variability measured for the startle response. The middle 52 trials (presented in pseudorandom order) consisted of 10 startle-only, 30 PPI trials (5 each of 6 different PPI trial
types), and 12 control trials (3 each of no pulse, 73, 76, or 82 dB only). The session
ended with 5 startle-alone trials. All of the trials were separated by an inter-trial interval
(ITI) of 8–23 s in length (average ITI = 15 s).
3.2.5. Behavioural measures
The magnitude of the first peak recorded following the startle pulse was used as
the measure of acoustic startle response and the average of each trial type was computed.
Startle responses on the first 2 trials were taken as a measure of initial startle reactivity.
For habituation during each session, the startle response of trials 3-10 was each divided
by the average of the first 2 trials to give normalized startle amplitudes. Within each test
session, a percent habituation score was also calculated using startle responses at the
beginning and end of the session. %Habituation = 100x (average of startle response on
trials 6-10 – average of startle response on last 5 trials of the session)/average of trials 610.
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Prepulse inhibition (PPI) was calculated for each prepulse level/ISI. %PPI = 100x
(Startle only magnitude – PPI startle magnitude)/Startle only magnitude. Similar to other
studies (Braff et al., 1999; Lockey et al., 2009), some groups of animals produced
prepulse facilitation (increased startle response with prepulse presentation) at the 73 dB
prepulse instead of inhibition. This can occur with prepulses that are too close to the
background noise. As a result, only 76 dB and 82 dB prepulses were analyzed for
prepulse inhibition.
3.2.6. Statistical analysis
All analyses were performed with IBM Statistics 20 (formerly Statistical Package
for the Social Sciences, SPSS). Outliers were identified as being ± 2 standard deviations
from the mean and were removed from analysis. As pups within a litter are not
independent samples, the effects associated with belonging to a litter and being raised in
a litter must be accounted for. To do this, linear mixed models were used for each of the
dependent variables, with Litter used as a subject variable. Fixed factors in most models
were: Session, Sex, Prenatal drug, Postnatal drug. For habituation across the first 10
trials, Session was removed and replaced by Trials, with a model used for each session
individually. Additionally, Prepulse level was added as a fixed factor into models for
each ISI level to assess prepulse inhibition. The random factor was startle box the animal
was tested in and covariates were body weight and litter size in all models. LSD posthocs were performed. Significance was set to

= 0.05.

3.3. Results
3.3.1. Initial startle reactivity
Each startle session began with 10 trials in which the startle pulse alone was
presented. Responses can vary greatly across the first few trials as animals acclimate to
the startle stimulus and a period of adjustment is desired prior to assessment of average
startle response and prepulse inhibition. However, the first trials can also provide a true
indication of initial startle reactivity prior to habituation (Geyer and Swerdlow, 2001).
The startle response for the first 2 trials of each session was analyzed to determine if
initial startle reactivity was influenced by prenatal or postnatal treatments.
Startle responses decreased from trial 1 to 2, with a significant effect of Trial,
F(1,777) = 15.30, p < 0.001 (data not shown) and decreased across Session,
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F(3,777) = 4.06, p = 0.007 (Session 1 significantly greater than Sessions 3 and 4, ps <
0.05). The Session x Sex x Prenatal drug x Postnatal drug interaction was significant,
F(9,777) = 2.10, p = 0.028. As there were no significant interactions between trials and
drug treatments, startle responses were collapsed across the first 2 trials for the 4 sessions
(Figure 3.1).
Effects of postnatal PPA treatment
On Session 1, there was a sex difference in the postnatal effect of PPA on startle
responses in the prenatal 2VEH control group. Postnatal PPA treated males in this group
showed significant hypo-responsiveness to startle compared to postnatal VEH (p =
0.007), while postnatal PPA treated females showed significant hyper-responsiveness to
startle compared to postnatal VEH (p = 0.048). This effect was not present on any other
sessions (Figure 3.1A).
Effects of prenatal LPS treatment
Prenatal LPS treatment produced hyper-responsiveness to startle in female
offspring postnatally treated with either PPA or VEH. In postnatal VEH treated females,
prenatal LPS produced significantly greater startle responses than 2VEH treatment
(p = 0.013), while in postnatal PPA treated females prenatal LPS produced significantly
greater startle responses than both prenatal PPA (p = 0.032) and 5VEH (p = 0.027)
treatments. These effects of treatment on initial startle responses were limited to Session
1 (Figure 3.1A).
Effects of prenatal PPA treatment
Prenatal PPA treatment alone did not influence startle on the first 2 trials until
Session 4. Prenatal PPA treatment produced significant hyper-responsiveness to startle
relative to prenatal 5VEH treatment in females for both postnatal PPA (p = 0.044) and
postnatal VEH (p = 0.046) and in males for postnatal VEH (p = 0.049, Figure 3.1D).
Effects of combined prenatal LPS or PPA and postnatal PPA treatment
Later test sessions showed effects of combined prenatal and postnatal treatment.
Postnatal PPA attenuated the effects of prenatal LPS treatment (Figure 3.1C, D). On
Sessions 3 and 4, prenatal LPS treatment produced hyper-responsiveness to startle in
male offspring compared to other prenatal treatment groups, but only in postnatal VEH
treated males (Session 3: 2VEH, p = 0.035, PPA, p = 0.016, and 5VEH, p = 0.023;
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Figure 3.1. Initial acoustic startle response collapsed across the first 2 trials for the 4
sessions.
On Session 1, postnatal PPA decreased startle in males and increased startle in females
(prenatal 2VEH group). Prenatal LPS increased startle initially in females (Session 1) and
increased startle developed in males (Session 3, 4). In later sessions, prenatal PPA treated
offspring also showed increased startle. Error bars represent SEM. Refer to Table 3.1 for
group designations and sample sizes. * p < 0.05, ** p < 0.01
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Session 4: 2VEH, p = 0.018 and 5VEH, p = 0.020). On Session 3, prenatal LPS-postnatal
VEH treated males also had significantly greater startle responses than prenatal LPSpostnatal PPA treated males (p = 0.002).
On Session 3, an effect of prenatal PPA in combination with postnatal PPA was
seen in male offspring. In postnatal PPA treated males, prenatal PPA produced
significantly greater startle responses than prenatal 5VEH (p = 0.043), 2VEH (p = 0.041),
and LPS (p = 0.038) treatments. This group (prenatal PPA-postnatal PPA) was also
significantly greater than males treated with prenatal PPA and postnatal VEH, p = 0.007
(Figure 3.1C).
In summary, on Session 1, postnatal PPA decreased startle in males and increased
startle in females in the prenatal 2VEH control group. Prenatal LPS treatment also
initially increased startle in females, with increased startle developing in later sessions in
males. The effect in males was attenuated with postnatal PPA. Lastly, increased startle
with prenatal PPA treatment developed in later sessions in both males and females.
3.3.2. Habituation
3.3.2.1. Habituation across the first 10 trials
To assess whether drug treatments affected habituation to the startle stimulus, the
first 2 trials of a session were averaged and trials 3-10 were normalized to this average. A
linear model was used to analyze each of the 4 sessions. There were significant effects of
Trial for all Sessions (1, 2: p < 0.001; 3: p = 0.001; 4: p = 0.020), but no significant
interactions with trial and treatments. By trial 10, startle responses were significantly
lower than the average response of trials 1 and 2 across all 4 Sessions

(ps < 0.05).

When data were divided into treatment groups, no animals displayed significant
habituation across the first 10 trials on Sessions 1, 3, and 4, with 6 of 16 treatment groups
on Session 2 showing habituation (trials 9 and 10 each significantly lower than the
averaged response of trials 1 and 2, ps < 0.05).
On Session 1, 2, and 4, significant Sex x Prenatal drug x Postnatal drug
interactions were found (1: F(3,891) = 7.26, p < 0.001; 2: F(3,894) = 6.68, p < 0.001; 4:
F(3,896) = 4.69, p = 0.003), and significant Sex x Postnatal drug (F(1,900) = 5.05,
p = 0.025) and Prenatal x Postnatal drug (F(3,906) = 11.94, p < 0.001) interactions were
found on Session 3 (Figure 3.2).

75

Effects of postnatal PPA treatment
In male offspring, there was an effect of postnatal PPA on normalized startle
amplitudes. Postnatal PPA produced significantly greater startle responses compared to
postnatal VEH in prenatal PPA treated males on Session 1 (p = 0.029), in LPS, 2VEH,
and 5VEH treated males on Session 3 (ps < 0.05) and in prenatal PPA and LPS treated
males on Session 4 (ps < 0.01).
Effects of prenatal LPS treatment
Limited to Session 2, prenatal LPS produced significantly greater startle
responses compared to the other 3 prenatal treatments in females treated with postnatal
VEH (2VEH, 5VEH, PPA, p < 0.01), and compared to prenatal 2VEH in females treated
with postnatal PPA (p = .035, Figure 3.2B).
Effects of combined prenatal PPA and postnatal PPA treatment
Prenatal PPA treatment alone did not significantly affect startle responses across
the first 10 trials. Prenatal PPA treatment combined with postnatal PPA treatment to
increase the startle response of female offspring on Sessions 1 and 2. Prenatal PPApostnatal PPA treated females produced significantly greater startle responses than the
other 3 prenatal groups treated with postnatal PPA (5VEH, 2VEH, LPS, p < 0.001), and
prenatal PPA treated females receiving postnatal VEH (p < 0.001) on Session 1. On
Session 2, this group was significantly greater than 5VEH and 2VEH females treated
with postnatal PPA (ps < 0.01, Figure 3.2A, B).
Figure 3.3B shows that prenatal PPA-postnatal PPA treated females were not
habituating to startle and were in fact sensitized across trials compared to the average of
trial 1 and 2 on Session 1 (trials 3-10, ps < 0.05). This effect was significant on Session 2,
but not as pronounced, with females prenatally exposed to PPA and postnatally to PPA
showing significantly greater startle responses than 5VEH and 2VEH females on trials 3,
5-7, ps < 0.05 (data not shown). By Session 3, the effects of prenatal and postnatal PPA
had disappeared, with Session 4 showing the opposite pattern to Session 1 and 2 (Figure
3.2C, D). Collapsed across trials, prenatal PPA in combination with postnatal PPA
treatment in females produced significantly lower startle responses compared to the other
prenatal groups combined with postnatal PPA (5VEH p = 0.018, 2VEH p = 0.006, LPS p
= 0.002).
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Figure 3.2. Habituation to the acoustic startle pulse across the 4 sessions.
Habituation to the startle pulse was assessed over the first 10 trials of each session.
Collapsed across trials, effects of prenatal PPA and postnatal PPA treatment were evident
in female, but not male, offspring. Females who received both prenatal and postnatal PPA
showed significantly increased startle on Sessions 1 and 2, with a decrease in Session 4
compared to other prenatal treatments. Error bars represent SEM. Refer to Table 3.1 for
group designations and sample sizes. * p < 0.05, ** p < 0.01, *** p < 0.001
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Figure 3.3. Habituation to the acoustic startle pulse on Session 1.
Session 1 habituation across trials 3-10 for A: Males and B: Females. Female offspring
who received prenatal and postnatal PPA displayed increased startle amplitudes
compared to other prenatal treatment groups. Trial 2 is the average of trial 1 and 2.
C: Percent habituation score between the beginning and end of the session. Animals
performed similarly at the beginning and end of the startle session, with the exception of
postnatal PPA treated male offspring in the prenatal 2VEH and PPA treated group. These
groups showed negative habituation, or sensitization, to startle at the end of the session.
This effect was present only on Session 1. Error bars represent SEM. Refer to Table 3.1
for group designations and sample sizes. * p < 0.05
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3.3.2.2. Percent habituation within session
The last 5 trials of each startle session were pulse alone trials. The average of the
peak startle response was taken along with the average of the peak startle response of
trials 6-10 in order to compute a percent habituation measure within each startle session.
A significant Session x Sex x Prenatal x Postnatal interaction was found, F(9,369) = 1.98,
p = 0.041, with some treatment groups showing sensitization (increased levels) at the end
of a startle session compared to the beginning.
On Session 1, an effect of postnatal PPA was found in male offspring prenatally
exposed to PPA or 2VEH, as these animals showed significant sensitization compared to
prenatal LPS and 5VEH (ps < 0.05) and to prenatal PPA and 2VEH males postnatally
treated with VEH (ps < 0.05, Figure 3.3C). This effect was only present on Session 1 as
the remaining sessions showed similar startle responses among male offspring. On
Session 2, female offspring in the prenatal 2VEH group postnatally treated with PPA
showed sensitization compared to the prenatal LPS, PPA, and 5VEH groups (ps < 0.01),
with no differences during the other 3 sessions (data not shown).
In summary, postnatal PPA treatment produced slight sensitization to startle in
male offspring. Prenatal LPS treatment increased startle responses in female offspring
only on Session 2. Most striking is the sensitization to startle in female offspring that
received both prenatal and postnatal PPA. This was present on Sessions 1 and 2, with
habituation occurring by Session 4 compared to other prenatal treatment groups.
3.3.3. Acoustic startle response
Following habituation to the first 10 trials, each startle session contained 10 startle
alone trials interspersed with prepulse-pulse, prepulse only, or no pulse trials. These 10
trials provided a measure of average startle response. There was a significant effect of
Session, F(3,361) = 6.06, p < 0.001, with startle responses during Session 1 greater than
the other 3 sessions. There were no interactions with Session. However, a significant
Sex x Prenatal drug x Postnatal drug interaction was found, F(3,376) = 5.08, p = 0.002
(Figure 3.4). Prenatal treatment with LPS produced significant hyper-reactivity to startle
in postnatal-VEH treated male offspring as compared to prenatal 2VEH (p = 0.025) or
5VEH treatments (p = 0.034). This was not found in male offspring postnatally treated
with PPA where startle responses were significantly lower in prenatal LPS-postnatal PPA
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Figure 3.4. Acoustic startle response collapsed across the 4 sessions.
There were no significant effects of prenatal or postnatal treatment in female offspring. In
male offspring, prenatal LPS produced a hyper-responsiveness to startle in postnatal VEH
treated animals, while this effect was attenuated in postnatal PPA treated animals. Error
bars represent SEM. Refer to Table 3.1 for group designations and sample sizes.
* p < 0.05, *** p < 0.001
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treated males as compared to prenatal LPS-postnatal VEH treated males (p < 0.001). No
significant effects of prenatal LPS in females, or prenatal and postnatal PPA in males and
females, on acoustic startle response were found.
3.3.4. Percent prepulse inhibition (%PPI)
Percent prepulse inhibition was assessed for the 76 dB and 82 dB prepulses at
each inter-stimulus interval (ISI, 60 ms and 100 ms). Inclusion of trials consisting of each
prepulse in the absence of the 115 dB pulse verified that animals were not startling to the
prepulses alone and that the drug treatments were not significantly different.
At the 60 ms ISI, %PPI increased across session, F(3,730) = 68.02, p < 0.001, and
increased as the prepulse intensity increased, F(1,730) = 82.93, p < 0.001. There were no
other significant effects of session or prepulse. The Sex x Prenatal drug interaction,
F(3,751) = 7.67, p < 0.001, indicated that while there were no differences in %PPI for
male offspring, female offspring prenatally exposed to PPA exhibited a significant
decrease in %PPI compared to females in the 5VEH control group, p = 0.037 (Figure
3.5). Further analysis showed that prenatal PPA resulted in a deficit in female offspring
on Sessions 2 (76 dB, p = 0.028), 3 (82 dB, p = 0.018), and 4 (76 dB, p = 0.023).
As with a 60 ms ISI, the 100 ms ISI also produced %PPI that increased across
session, F(3,728) = 32.70, p < 0.001, and increased as the prepulse intensity increased,
F(1,728) = 250.05, p < 0.001. There was a significant Sex x Prenatal drug x Postnatal
drug interaction, F(3,746) = 3.57, p = 0.014 (Figure 3.6). In prenatal 2VEH treated male
offspring, postnatal PPA produced significantly greater %PPI than postnatal VEH, p =
0.003. This effect was present on Sessions 1 (82 dB, p = 0.026), 2 (p = 0.049, NS on each
prepulse), and 4 (82 dB, p = 0.045). In female offspring, postnatal PPA had the reverse
effect in the 2VEH group, with postnatal PPA significantly decreasing %PPI compared to
postnatal VEH, p = 0.017 (Session 3, 82 dB, p = 0.042; Session 4, 76 dB, p = 0.039).
Limited to Session 1, there was a difference in the prenatal control groups in female
offspring postnatally treated with PPA as females in the 2VEH group had significantly
lower %PPI than the 5VEH group (76 dB, p = 0.020). The 100 ms ISI also produced a
Session x Sex x Prenatal drug interaction, F(9,728) = 2.07, p = 0.030. On Session 2,
females in the prenatal PPA group showed significantly less %PPI than 5VEH females, p
= 0.006 (76 dB, p = 0.011).
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Figure 3.5. Percent prepulse inhibition (%PPI) with 60 ms inter-stimulus interval.
The amount of prepulse inhibition increased as prepulse intensity increased, no
interactions with treatments were found. A: Sex x Prenatal drug interaction was
significant. Females in the prenatal PPA treated group displayed significantly decreased
prepulse inhibition compared to 5VEH treated controls. B: Data displayed across
prepulse level. Error bars represent SEM. Refer to Table 3.1 for group designations and
sample sizes. * p < 0.05
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Figure 3.6. Percent prepulse inhibition (%PPI) with 100 ms inter-stimulus interval.
The amount of prepulse inhibition increased as prepulse intensity increased, no
interactions with treatments were found. A: Sex x Prenatal drug x Postnatal drug
interaction was significant. In the prenatal 2VEH treated group, postnatal PPA decreased
prepulse inhibition in female offspring and increased PPI in male offspring. B: Data
displayed across prepulse level. Error bars represent SEM. Refer to Table 3.1 for group
designations and sample sizes. * p < 0.05, ** p < 0.01
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Overall, prenatal LPS did not significantly affect prepulse inhibition. Prenatal
PPA treatment produced a %PPI deficit in female, but not male, offspring at both ISIs.
This effect was more evident at the 60 ms ISI. Additionally, at the 100 ISI, there was a
sex difference in the effects of postnatal PPA, with males showing increased %PPI and
females showing decreased %PPI.
3.4. Discussion
Prior investigations of the effects of prenatal and postnatal immune activation and
the effects of GI microbial metabolites have been limited to adult rodents. In the present
study, the acoustic startle response (ASR), habituation to this response, and prepulse
inhibition in male and female adolescent rat offspring was evaluated following prenatal
treatment with the immune stimulant, lipopolysaccharide, or the short chain fatty acid,
PPA. Rat offspring were further administered a PPA regimen in the second week of life
to see if a postnatal insult would further exacerbate any behavioural effects of prenatal
treatment.
Prenatal LPS produced pronounced hyper-sensitivity to startle in males, but not
females, while prenatal and postnatal PPA each produced transient effects on startle
response in both males and females. A deficit in prepulse inhibition in female offspring
prenatally exposed to PPA was present, while prenatal LPS and postnatal PPA did not
alter prepulse inhibition. In addition, evidence supporting a double-hit hypothesis was
apparent in females, showing that further environmental insults during development can
exacerbate the effects of a prenatal insult. The combination of prenatal and postnatal
PPA produced an increased, or sensitized, startle response over the first 10 startle trials,
rather than habituation. Among all animals, there was little habituation to startle. Taken
together, the present results indicate that prenatal LPS or PPA, postnatal PPA, and
combined prenatal and postnatal PPA treatments can produce subtle and sexually
dimorphic effects on sensory processing in adolescent rats. Effects on sensory processing
were specific to each treatment and are discussed below.
3.4.1. Prenatal LPS treatment influenced acoustic startle response, not prepulse
inhibition
Prenatal treatment with LPS on G15-16 produced significant effects on startle
responses, with increased startle responses to initial stimuli in females and throughout the
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startle testing session in males. Females acclimated to the acoustic pulse after Session 1,
with hyper-sensitivity to the first trials disappearing. In male offspring, a pattern of
hyper-sensitivity to initial trials did not develop until Sessions 3 and 4. Additionally,
prenatal LPS affected the average peak startle response in the bulk of the testing session,
with males hyper-sensitive to acoustic startle, regardless of test session.
These results suggest that with a low dose of prenatal LPS, startle behaviour is
altered in a sex-specific manner in adolescent offspring; transiently in female offspring
(to novel stimuli) and more permanently in male offspring. Interestingly, hyperresponding was non-significant in prenatal LPS males postnatally treated with PPA when
it was hypothesized that an exacerbation with the 2 treatments might occur. However,
valproic acid (VPA) and sodium butyrate (a SCFA) have been shown to decrease LPSinduced proinflammatory responses via their activity on gene expression as histone
deacetylase inhibitors (Chen et al., 2007). PPA can also act as a histone deacetylase
inhibitor (Nguyen et al., 2007) and may have similarly countered effects of LPS
treatment.
There is limited information on the effects of maternal immune activation (MIA)
on ASR in adolescent rats. Most startle response studies report prepulse inhibition and do
not report ASR data. Where reported, MIA on G15 using the viral mimetic, poly I:C, has
been found to produce no change in startle responses in adolescent male (Wolff et al.,
2010) and adolescent male and female rats (Howland et al., 2012). The present findings
of hyper-sensitivity to acoustic startle in male and, to a lesser extent, female adolescent
rats with MIA using LPS are novel and suggest developmental differences in responses.
Female adolescent rats are hyper-responsive to an acoustic startle stimulus for a
short time and then acclimate, while males showed more long-term effects. This pattern
of immune activation during development affecting the behaviour of males and not
females has been previously reported with postnatal LPS and adult rats (Tenk et al., 2008;
Tenk et al., 2013). Sex differences in the innate immune response, with males more
susceptible to immune stimulation and females better able to handle an immune insult,
may be related to estrogen modulated cytokine gene expression (Dimayuga et al., 2005;
Klein, 2012).
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Hypersensitivity to startle with prenatal LPS administration has been shown in
adult male rats. Fortier et al. (2004) report increased startle responses in adult males with
LPS administered at the same dose as the present study (50 g/kg) on G18-19, but did not
find changes in males when a higher dose of LPS (100 g/kg) was administered on G1516 (Fortier et al., 2007). Injection later in gestation tends to increase risk of infant
mortality and, as such, an increased sensitivity at G18-19 is observed. No change in ASR
in adult males with prenatal LPS exposure at G15-16 suggests that adolescent rats may be
more vulnerable to the effects of maternal LPS.
Repeated LPS administration for the duration of gestation produced mixed results
on ASR in adult males and females. Increased startle responses were found in both male
and female offspring (Basta-Kaim et al., 2011), while Borrell et al. (2002) found no
change in ASR in males or females. Clearly, the effects of prenatal LPS appear to be
influenced by the intensity and timing of immune system activation and, as the present
study demonstrates, the age at which offspring are tested.
Contrary to previous results, prenatal LPS treatment did not alter prepulse
inhibition in male and female adolescent offspring. Romero et al. (2010) found decreased
prepulse inhibition in male and female adolescent offspring exposed to LPS throughout
gestation. Similar effects are reported with poly I:C administered on G12 (Deslauriers et
al., 2013) or G15 (Howland et al., 2012). This is consistent with PPI deficits observed in
adult male and female offspring following MIA (Basta-Kaim et al., 2011; Fortier et al.,
2007; Howland et al., 2012; Smith et al., 2007). LPS was administered at a low dose and
a fixed time (G15-16) in the present study. Time of injection, dose, and immune
stimulant affect the subsequent effects on offspring, and the present dose was not
sufficient to produce changes in prepulse inhibition. It is interesting that prenatal LPS
produced alterations in acoustic startle response in the absence of PPI deficits, reinforcing
the idea that differing levels of severity of maternal immune insult at similar time points
in development may produce different behavioural phenotypes.
In summary, maternal immune activation with the bacterial mimetic, LPS, altered
sensory processing of acoustic startle, with intact prepulse inhibition, in adolescent rats.
Effects of LPS were sexually dimorphic, as hyper-responding to acoustic startle was
more permanent in male offspring and occurred only to novel stimuli in female offspring.
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Importantly, these results demonstrate that a low dose of LPS can alter sensory
processing in adolescence at a dose that has been shown to not alter adult startle
responses. In light of the male prevalence in ASD, bacterial infection during gestation
may influence sensory responsiveness to stimuli.
3.4.2. Prenatal PPA and postnatal PPA treatment alone each influenced acoustic
startle response and prepulse inhibition
Prenatal PPA treatment produced hyper-sensitivity to the initial startle trials (first
2 trials of a session) in both male and female offspring on the last session, following
repeated experience with the startle pulse. In contrast, postnatal PPA affected initial
responses to startle stimuli only on Session 1. Male offspring were hypo-sensitive and
female offspring were hyper-sensitive to acoustic startle. Unlike prenatal LPS treatment,
the effects of prenatal and postnatal PPA were present only for the first trials of the startle
test as results for the average peak response to acoustic startle in the bulk of the session
(during prepulse inhibition trials) did not show an effect of prenatal PPA or postnatal
PPA. It appears that animals treated with prenatal or postnatal PPA have altered
sensitivity to sudden stimuli, but with repeated presentations within a session, are quickly
able to adapt their responses.
Habituation measures showed that postnatal PPA enhanced startle in male
offspring, in a non-specific manner, across trials 3-10 of a session and enhanced within
session startle (sensitization) on Session 1, while no effects were observed in female
offspring. Males habituated to startle within a session similarly to other groups on
Sessions 2-4. This effect in postnatal PPA treated males could indicate a delay in
habituation compared to other animals. Perry et al. (2007) report habituation to acoustic
startle in adults with ASD; however, while the end result was habituation, it took longer
for ASD patients to reach that habituation across trials.
Although this is, to date, the first study assessing the effects of prenatal and
postnatal PPA on acoustic startle in rat offspring, comparisons to previous studies using
environmental toxins as models for neurodevelopmental disorders can be made. One of
the most widely used toxins in models of autism is valproate (VPA). Again, most work
has been carried out with adult offspring and ASR is rarely reported. Hypo-sensitivity
(Vorhees, 1987) and no change in ASR (Markram et al., 2008) has been reported in adult
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male and female offspring prenatally exposed to VPA, while Dendrinos et al. (2011)
report hypo-sensitivity in juvenile offspring following prenatal VPA, but did not separate
males and females. A study using postnatal VPA in the first week of life also found hyposensitivity in both male and female adolescent rats (Reynolds et al., 2012). Postnatal PPA
treated male adolescent rats also showed hypo-sensitivity to startle on the first 2 trials of
Session 1.
Other toxins have also been administered prenatally in rats. As mentioned above,
MIA produced hyper-sensitivity to startle. Zerrate et al. (2007) reported hypersensitivity
to acoustic startle in female adolescent offspring following postnatal treatment (first week
of life, P2-5) with terbutaline, a drug administered to arrest preterm labor in humans.
Hypersensitivity in the current study suggests the effects of PPA may be similar to these
toxins. It may also be the case that the ASR profile with PPA administered at various
times in development has a distinct profile. Prenatal PPA and postnatal PPA in the
second week of life produced hypersensitivity to startle across the first 10 trials in the
current study, while postnatal PPA in the first week of life produced no change in startle
across the first 10 trials (unpublished data).
Prenatal and postnatal PPA each produced a prepulse inhibition deficit in female
adolescent offspring. Prenatal PPA did not alter prepulse inhibition in male offspring, but
produced a decrease in prepulse inhibition in female offspring at both ISIs (60 and 100
ms). Both of these intervals are used in the human literature with ASD patients, while
100 ms is often used in behavioural rodent studies in order to draw comparisons with
human literature. Although it is unclear why this decrease was only significant on later
sessions and not on session 1, it does emphasize the utility of repeated testing. Similar to
prenatal PPA, females treated with postnatal PPA showed a decrease in prepulse
inhibition, but males showed an increase in prepulse inhibition. This increase in males
could also be interpreted as a deficit, with fixation on prepulse processing resulting in an
inability to respond appropriately to stimuli in the environment. A similar pattern was
observed in previous work with postnatal PPA in the first week of life increasing prepulse
inhibition in female, not male offspring (Foley et al., 2009).
A deficit in prepulse inhibition is consistent with previous animal work with VPA
and MIA models. Decreases in prepulse inhibition have been reported following MIA in
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both male and female treated adolescent offspring (Howland et al., 2012; Romero et al.,
2010) and prenatal VPA in adolescent males and adult males and females (Markram et
al., 2008; Schneider et al., 2005). Postnatal VPA also produced a prepulse inhibition
deficit in both male and female adolescent rats (Reynolds et al., 2012).
The present results indicate that prenatal and postnatal PPA alone affects sensory
processing in adolescent offspring. Subtle effects on acoustic startle responses in both
male and female adolescent offspring, and sustained effects on prepulse inhibition were
observed. Effects on prepulse inhibition were sexually dimorphic, with prenatal PPA
producing a decrease in females and no change in males, and postnatal PPA producing a
decrease in females and an increase in males.
3.4.3. Combined effects of prenatal and postnatal PPA: Evidence for the double hit
hypothesis
The combination of prenatal and postnatal PPA produced augmented startle
responses in female offspring, but not male offspring. Prenatal PPA in combination with
postnatal PPA showed increased normalized startle across trials 3-10 for the first 2
sessions in female offspring, showing a sensitized startle response that was not observed
in other animals. Females with this ‘double-hit’ of PPA require longer adjusting to the
startle stimuli compared to other treatment groups. Increased startle responses return to a
level similar to other animals as repeated sessions occur, suggesting a heightened
sensitivity to repeated stimuli that gradually adapts. There was no evidence of a double
hit effect in males or for prepulse inhibition in males and females. Coupled with the
effects of prenatal PPA on prepulse inhibition in female offspring, it appears that female
offspring were more susceptible to PPA induced alterations in behaviour. In this respect,
anxiety and gut-derived illnesses are more prevalent in females over males (Donner and
Lowry, 2013; Tang et al., 2012). That the main source of endogenous PPA is from
metabolism by enteric bacteria could link the susceptibility of females to the
developmental effects observed in the current study.
Combined PPA effects in adolescence could distinguish this treatment from that
of prenatal LPS and MIA. Yee et al. (2011) found no evidence for a double hit hypothesis
in adult rats using prenatal poly I:C (G15) and juvenile stress (P27-29), with no combined
effects of treatment on ASR and prepulse inhibition, while evidence for a double hit
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hypothesis has been reported in adult mice following combined prenatal poly I:C (G9)
and adolescent stress (P30-40) (Giovanoli et al., 2013). Prenatal LPS combined with
postnatal PPA did not produce enhanced effects. This may be a product of timing of
administration, or the type of insult, as studies of postnatal LPS administration have
shown augmented responses of rats with subsequent insults of LPS or stress in adulthood
(Tenk et al., 2008; Walker et al., 2009). Previous work with postnatal PPA in the first
week of life and adolescent PPA challenge increased habituation across the first 10 startle
trials in male rats (unpublished data). In a more naturalistic setting, both LPS and PPA
together would be produced by enteric bacteria, along with other SCFAs. Future
investigation warrants combining LPS and PPA into one insult and/or combining these
environmental toxins with a genetic animal model. Regardless, the effects of a ‘double
hit’ of PPA suggest that multiple environmental insults, perhaps altering immune
responses, can have sexually dimorphic effects on sensory behaviour in adolescent rats.
3.4.4. Lack of habituation and effects of vehicle injections on behaviour
The effect of trial indicated that normalized startle responses were significantly
lower at trial 10 than at the beginning of the session, suggesting habituation to acoustic
startle. However, when animals were divided by treatment group this habituation was no
longer present. Methodology may account for the lack of progressively decreasing
responses to startle in all treatment groups, including controls. A larger number of trials
(e.g., 30) may be required to produce habituation of the startle response and/or constant
inter-trial intervals facilitate habituation (Geyer et al., 2001; Schmid et al., 2011). Wolff
and Bilkey (2008) also used a small number of trials at the beginning and end of their
startle session to assess habituation and also found no change in startle in MIA treated or
control animals.
It is also very interesting to note that there were some significant differences in
offspring behaviour of those rats that were prenatally exposed to 2 or 5 vehicle control
injections; specifically, that there were effects of postnatal PPA on acoustic startle and
prepulse inhibition in 2VEH, but not 5VEH animals. Laboratory procedures can alter
physiological and hormonal parameters in rodents. For example, repeated vehicle
injections can alter baseline levels of plasma corticosterone (Balcombe et al., 2004;
Drude et al., 2011; Ryabinin et al., 1999). Furthermore, with prenatal stress, the enzyme
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11 -hydroxy steroid dehydrogenase Type II (11 -HSD2) that normally protects the fetus
from maternal cortisol can be downregulated in animals and humans, exposing the
developing animals and the fetus to cortisol (O'Donnell et al., 2009). Prenatal stress can
result in anxiety-like behaviour and increased responding to novelty in offspring (Henry
et al., 1994; Fride and Weinstock, 1988). In fact, prenatal handling and saline injection
can produce hyper-sensitivity to acoustic startle on first presentation of the stimulus in
male offspring (White and Birkle, 2001). A stress response associated with saline
injections, although quite mild in comparison to maternal stress paradigms, may have
been enough of a stressor to alter development and mask the effects of postnatal PPA.
3.4.5. Potential neurodevelopmental changes from LPS and PPA administration
Alterations in neurodevelopment in excitatory and/or inhibitory
neurotransmission may have contributed to the effects of treatments on ASR. Glutamate
is the major neurotransmitter mediating the acoustic startle response in the midbrain, with
GABA receptor blockade shown to increase the ASR (Koch and Schnitzler, 1997).
Decreased GABA could alter excitation/inhibition balance and lead to less inhibition of
glutamatergic inputs in the startle pathway. Fear or anxiety to the startle stimuli could
account for the subtle effects on startle responses. Inputs from the amygdala modulate
startle and are involved in sensitization and fear-potentiation of startle (Koch and
Schnitzler, 1997; Van Nobelen and Kokkinidis, 2006). In the case of prenatal LPS in
females and prenatal and postnatal PPA in males and females, these are subtle alterations
as offspring are able to adjust their behaviour over repeated startle sessions and respond
to startle similar to other animals, perhaps through learning that the stimuli are not
threatening. Associations have been made between sensory abnormalities and increased
anxiety in children with ASD (Goldsmith et al., 2006; Pfeiffer et al., 2005).
Supporting the possibility of PPA induced developmental alterations in
neurotransmission are reports of a PPA-laced diet administered throughout prenatal and
postnatal life produced altered cortical migration, increased synaptic density, and reduced
inhibitory interneurons in the cortex of rat offspring (Taylor et al., 2013) while orally
administered PPA depleting GABA in young rat brains (El-Ansary et al., 2011). SCFAs
and VPA may gain access to the developing fetus through active transport via
monocarboxylate transporters in the placenta (Nagai et al., 2010; Ushigome et al., 2001).
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It should be noted that the effects of PPA and SCFAs on biological systems are broad
(MacFabe, 2012), and also, at many levels, may be beneficial (Al-Lahham et al., 2010).
Prenatal LPS has recently been shown to decrease the number of GABA neurons
in adult offspring and alter expression of genes regulating the migration of GABAergic
interneurons, important for proliferation, migration, and synaptogenesis in early
development (Nouel et al., 2012; Oskvig et al., 2012; Owens and Kriegstein, 2002). This
may contribute to an imbalance in excitation/inhibition, favouring excitability of neural
circuits. Increases in the proinflammatory cytokines IL-1 , IL-6, and TNF- in the
amniotic fluid and the fetal brain with LPS treatment may also contribute to adverse
outcomes (Gayle et al., 2004; Ning et al., 2008; Oskvig et al., 2012).
Prepulse inhibition is modulated by prefrontal and mesolimbic dopamine inputs to
the brain stem. Dopamine and serotonin antagonists, and norepinephrine agonists can
decrease prepulse inhibition (Koch, 1999). PPA may alter gene expression of
catecholamine synthesis. Butyrate (a SCFA) and VPA, both histone deacetylase
inhibitors, both increase transcription of the tyrosine hydroxylase (TH) gene in PC12
cells, in vitro (DeCastro et al., 2005; D'Souza et al., 2009). PPA also acts as a histone
deacetylase inhibitor (Nguyen et al., 2007; Phiel et al., 2001) and preliminary results have
shown that central administration of PPA can alter gene expression in ASD associated
genes (Nankova et al., 2012).
3.4.6. Relevance for autism spectrum disorders
An imbalance between excitation and inhibition within neural circuits may
explain behavioural impairments observed in autism, with alterations in GABA suggested
to be critical. A meta-analysis reports that multiple ASD mouse models share a decrease
in GABA cells in the cortex (Gogolla et al., 2009). The cortex is organized into
minicolumns, consisting of glutamatergic and GABAergic neurons. In autistic patients,
minicolumns in the frontal and temporal cortex were narrower and less compact than
controls (Casanova et al., 2002), while there was a 50% reduction in enzyme protein
levels responsible for GABA synthesis in parietal and cerebellar areas (Fatemi et al.,
2002). A decrease in inhibition may impair neural circuit maturation and/or leave neural
circuits in a hyper-excitable state, resulting in either withdrawing or hyper-reacting to
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environmental stimuli in order to cope (Markram et al., 2008; Rubenstein and Merzenich,
2003).
In reports of MIA or VPA animal models of neurodevelopmental disorders,
prepulse inhibition is frequently used in behavioural test batteries, acoustic startle
response is less frequently reported, and habituation to acoustic startle rarely investigated.
Behavioural startle response studies often discard the first trials from analysis. Current
results suggest that it may be useful to include habituation measures in acoustic startle
testing. It may also be informative to use different modalities (e.g., tactile, heat) as
multiple sensory abnormalities in ASD have been reported that do not include acoustic
(Leekam et al., 2007).
Prepulse inhibition deficits have not been extensively investigated in the ASD
population and very few reports have been published, with conflicting results (McAlonan
et al., 2002; Oranje et al., 2013; Perry et al., 2007). Prepulse inhibition is governed by
long term neural connections between prefrontal/striatal regions, midbrain, and brain
stem. As ASD may involve impaired long-range neural connectivity (Shukla et al., 2011),
including prepulse inhibition in a behavioural test battery has utility.
3.4.7. Concluding Remarks
In summary, this study is the first, to date, to assess the effects of prenatal and
postnatal PPA, and one of a few assessing effects of prenatal LPS, on the acoustic startle
response and prepulse inhibition in both male and female adolescent offspring. The
results highlight the importance of using both male and female rats in developmental
neuroscience and provide new information on adolescent rats. Prenatal LPS increased the
acoustic startle response in adolescent males, while postnatal PPA altered initial startle
responses in both male and female offspring. A greater effect on habituation to the startle
response was observed in females who received a double hit of PPA, prenatal and
postnatal. A decrease in prepulse inhibition in female offspring prenatally and postnatally
exposed to PPA was present, postnatal PPA increased prepulse inhibition in males, and
prenatal LPS did not alter prepulse inhibition. These results provide evidence that byproducts of enteric bacteria metabolism can alter development and behaviour in ways that
resemble sensory problems observed in ASD. Repeated infection or immune insult
throughout gestation and early life may influence the gut microbiome and lead to
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production of metabolic products that alter neurodevelopment in susceptible populations.
That different developmental time points of PPA administration produced different
behavioural phenotypes illustrates how one environmental insult may contribute to a
range of disorders on the autism spectrum.
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Chapter 4
Prenatal exposure to the enteric bacterial metabolic product, propionic acid, and
the bacterial mimetic, lipopolysaccharide, alters social behaviour in neonatal,
adolescent and adult male and female rats
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4.0. Summary
Emerging evidence suggests the gut microbiome plays an important role in immune
functioning, behavioural regulation and neurodevelopment. Altered microbiome
composition, including elevated short chain fatty acids, and/or immune system
dysfunction may contribute to autism spectrum disorders (ASD) with some children with
ASD exhibiting both abnormal gut bacterial composition and immune system
dysfunction. This study describes the effects of prenatal propionic acid (PPA), a short
chain fatty acid and metabolic fermentation product of antibiotic resistant enteric
bacteria, and of prenatal lipopolysaccharide (LPS), a bacterial mimetic, on social
behaviour in male and female neonatal, adolescent and adult rats. Pregnant Long-Evans
rats were injected once a day with either a low level of PPA (500 mg/kg SC) on gestation
days G12-16, LPS (50 g/kg SC) on G12, or vehicle control on G12 or G12-16. Sex- and
age-specific, subtle effects on behaviour were observed. Both male and female PPA
treated pups were impaired in their nest seeking response test, suggesting impairment in
olfactory recognition at a very young age. As well, adolescent males born to PPA treated
dams approached a novel object more than control animals and showed increased levels
of locomotor activity compared to prenatal PPA females. Prenatal LPS produced subtle
impairment in social behaviour in male and female adults. These sex differences, with
males affected more by treatments, are consistent with the male predominance in ASD.
These findings raise the possibility that prenatal exposure to elevated levels of
microbiome products, such as PPA, can subtly influence neonatal, adolescent and adult
social behaviour.
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4.1. Introduction
Attention has increasingly focused on how host gut microbial populations, known
as the microbiome, influence health. Through communication with the central and
peripheral nervous system, modification in the various components of the microbiome
have the potential to contribute to gastrointestinal (GI), immune, and neuropsychiatric
disease (Cryan and Dinan, 2012; Nicholson et al., 2012). Results of recent studies with
germ-free mice have demonstrated that alterations in the GI microbiome are associated
with changes in early gene expression, neurotransmitter turnover, stress response, as well
as reduced social behaviour (e.g., Desbonnet et al., 2013; Foster and Neufeld, 2013;
Heijtz et al., 2011).
There is also mounting evidence alterations in the composition of the microbiome
may also contribute to the development and/or maintenance of autism spectrum disorders
(ASD) in children. Autism spectrum disorders (ASD) are a broad range of
neurodevelopmental disorders of unclear etiology. ASD are behaviourally diagnosed,
with impairments in verbal and social communication, social behaviour, sensory
functioning, and stereotyped and repetitive behaviour (Patterson, 2011). There are a
number of comorbid traits in ASD, including a subset of patients that have
gastrointestinal (GI) symptoms which can include increased permeability or
inflammation of the intestinal tract. Indeed, the severity of autistic symptoms has been
associated with severity of GI dysfunction in some patients (Adams et al., 2011; Horvath
and Perman, 2002).
Abnormal levels of bacteria flora, including augmented Clostridia, Bacteroidetes,
and Desulfovibrio subtypes, have been found in the GI tract of autistic children (Finegold
et al., 2012; Parracho et al., 2005). Metabolic products of these include the short chain
fatty acids (SCFA, from carbohydrate metabolism) (Finegold et al. , 2010) which at
normal levels are essential for normal and immune associated functions (Al-Lahham et
al., 2010), but at higher levels may alter immune function and/or exacerbate ASD
behaviours.
The SCFA, propionic acid (PPA), produced by enteric bacteria, has been
proposed as a potential environmental factor in the development of ASD. Elevated levels
of PPA characterize the neurodevelopmental metabolic disorder propionic acidemia
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(Feliz et al., 2003), with Al-Owain et al. (2013) recently reporting a case study of
propionic acidemia and ASD comorbidly. Central and peripheral administrations of PPA
in male rats have produced brain and behavioural changes consistent with ASD
(MacFabe et al., 2007; MacFabe et al., 2011; MacFabe, 2012; Shultz et al., 2008; Thomas
et al., 2012). PPA may exert its effects through a variety of modes including immune
dysregulation, inflammation, oxidative stress, mitochondrial dysfunction, and epigenetic
actions through inhibition of histone deacetylase, all of which have been associated with
ASD (Frye et al., 2013; MacFabe, 2012; Rossignol and Frye, 2012).
Several studies have linked maternal infections or inflammation during pregnancy
to the development of ASD (reviewed by Patterson, 2011). An immune insult during
critical periods, and the accompanied release of proinflammatory cytokines acting both
peripherally and centrally, may have adverse consequences for neurodevelopmental
processes, such as cell differentiation, migration, and synaptogenesis (Bilbo and Schwarz,
2012; Patterson, 2011).
Maternal immune activation (MIA) in rodents has been used to investigate the
role of the immune system in various behavioural disorders including that of ASD using a
number of agents to induce an inflammatory response (e.g., the viral mimetic,
polyinosinic:polycytidylic acid (poly I:C) and the bacterial mimetic, lipopolysaccharide).
Lipopolysaccharide (LPS) is not only the major component of the cell wall of Gramnegative bacteria but also is a by-product of metabolism of many enteric bacteria.
Offspring of dams treated with these immune agents display behavioural deficits in
exploratory behaviour and social interaction (Smith et al., 2007). Prenatal treatment with
other environmental agents, such as valproate (VPA), an epilepsy treatment that increases
the risk of ASD and a precursor of PPA, also produces alterations in social behaviour in
adolescence and adulthood rats (Kim et al., 2013; Schneider and Przewlocki, 2005).
Impairments in social behaviour have been reported following acute and central
administration of PPA in male adolescent and adult rats, both in social interaction and
social approach (MacFabe et al., 2011; Shultz et al., 2008), but to date, there have been
no investigations of the potential effects of prenatal PPA on social behaviour. Likewise,
there are also relatively few reports on the effects of prenatal LPS on social behaviour in
either adult or, in particular, adolescent male and female rats. LPS administered in early
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or mid-late gestation resulted in decreased social play behaviour and interaction in male
adolescent and adult rats (Taylor et al., 2012; Kirsten et al., 2010). MIA at G12.5 also
decreased social approach in adult mice (Malkova et al., 2012; Smith et al., 2007).
The present study investigated the effects of prenatal treatment with either LPS or
the microbiome metabolite, PPA, on social and related behaviour in male and female
neonatal, adolescent, and adult rats. Low doses of LPS and PPA were used to examine if
subtle changes in the components of the microbiome and its products can affect
development. Following administration of prenatal LPS and prenatal PPA, a variety of
social behaviour measures were assessed throughout the lifespan of male and female
offspring. It was hypothesized that prenatal LPS and PPA would affect social behaviour
in adolescent and adult rats.
4.2. Methods
4.2.1. Animals
Female Long-Evans rats (230-305 g) were mated with adult males (370-575 g,
Charles River, Canada) for a total of 16 litters. Females were paired with a male the night
before behavioural estrus. Sperm present on a vaginal smear (hematoxylin and eosin
stain) the next morning indicated successful mating and this was designated as gestational
day 0 (G0). Dams were housed individually in standard polypropylene cages (45 x 22 x
20 cm) with ad libitum access to both food (ProLab RMH 3000) and water. A 12/12 h
light-dark cycle (lights on at 07:00 h) was maintained in a temperature controlled colony
room (21 ± 2°C). Litters were born on G22 (designated as postnatal day 0 (P0)), toeclipped for identification, and were weaned at P21. Prenatal treatments did not differ in
pregnancy length (22 days) and there were no significant differences in litter size
between treatment groups (M = 13.06 pups, SD = 2.67). On P21, pups were weaned and
culled to 8 or 10 animals per litter. Weaned rats were housed in same-sex, same-drug
groups of 2-3, in standard polypropylene cages under the same conditions as dams, unless
otherwise stated. All behavioural testing took place during the light phase. Body weight
was monitored weekly. All procedures were approved by the University of Western
Ontario Animal Use Subcommittee and were in accordance with the Canadian Council of
Animal Care (CCAC) guidelines.
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4.2.2. Prenatal LPS and PPA administration
Sodium propionate (PPA, P1880, Sigma Chemical, St. Louis, MO, USA) was
dissolved in 0.1 M phosphate buffered saline and administered at a dose of 500 mg/kg SC
(250 mg/mL, pH corrected to 7.4 with concentrated HCl) once a day on G12-16 for a
total of 5 injections. Injections started on G12 to mimic the VPA model of ASD
(Schneider and Przewlocki, 2005). Multiple injections were administered given the short
half-life of PPA (20 min, Brusque et al., 1999). Lipopolysaccharide (LPS from E. coli
serotype 0111:B4, L2630, Sigma Chemical, St. Louis, MO, USA) was dissolved in 0.1 M
phosphate buffered saline and administered SC at a dose of 50 g/kg on G12 based on
other studies of MIA (e.g., Smith et al., 2007). Phosphate buffered saline was injected SC
as a vehicle control to yield two control groups, either on G12 (VEH) or on G12-16
(5VEH). All injections were between the shoulder blades.
4.2.3. Experimental procedures
4.2.3.1. Nest seeking behaviour (Olfactory discrimination), P9-11
All pups (n=209) underwent determinations of nest seeking response behaviour
(VEH: Male n=21, Female n=31; LPS: Male n=23, Female n=28; 5VEH: Male n=26,
Female n=23; PPA: Male n=33, Female n=24). On P9, 10, and 11, pups were individually
placed in the centre of a plastic cage (28 cm x 17.5 cm x 13 cm) with either home or
clean bedding placed on filter paper (Whatman No. 1, Whatman International Ltd.,
England) at each end of the cage, 10 cm from the centre. Bedding was 3 days old for all
of the tests and the side of the cage that each bedding was placed on was counterbalanced across trials. The time (s) to reach the home bedding was measured, with a
maximum score of 180 s. A choice was made when the rat pup’s head emerged in the
bedding or when all 4 feet were resting on the bedding. The apparatus was cleaned in
between animals. This test is considered to reflect a nest-seeking response mediated by
the olfactory system (Gregory and Pfaff, 1971).
4.2.3.2. Open-field activity and adolescent social interactions, P30-33
Litters were culled at weaning (n=126), and these animals were behaviourally
tested in adolescence and adulthood (VEH: Male n=16, Female n=16; LPS: Male n=16,
Female n=14; 5VEH: Male n=14, Female n=18; PPA: Male n=16, Female n=16).
Behaviour was evaluated in a circular open-field arena (90 cm diameter, 40 cm high)
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with Beta Chip bedding covering the floor. A CD camera was mounted to the ceiling
above the centre of the arena and connected to a computer, allowing behaviour to be
recorded using the EthoVision 3.0.15 Behavioural Monitoring and Analysis System
(Noldus Information Technology) at a rate of 5.994 frames/s. The x-y coordinates of each
animal in the arena are tracked and several variables quantified. The camera was also
connected to a DVD-R, allowing recordings for experimenter manual scoring.
Habituation to the circular open-field arena took place from P30-32. Animals
were placed individually into the centre of the open-field for 15 min and the following
locomotor activity variables were monitored: total distance – total horizontal distance
traveled in cm; movement time – time in seconds spent in horizontal movement; velocity
– distance traveled per unit time (cm/s); vertical time – time in seconds an animal spent
rearing; percent time spent in periphery – time in seconds spent in the outer third of the
open-field.
On P33, animals were individually housed for 3 hours to encourage social
interaction. Following this brief period of social isolation, animals were placed at
opposite sides into the open-field in same-sex, same-prenatal drug pairs to assess social
interaction. Members of a pair were from the same litter, but were not cage-mates since
weaning. Total locomotor activity and social behaviour was recorded for 15 minutes.
Immediately prior to being placed in the open-field (and the day before as a habituation),
the dorsal surfaces of rats were colored with black, non-toxic marker so that the
EthoVision system could identify individuals. One member of a pair had the entire dorsal
surface colored and the second member had the natural black markings on the dorsal
surface colored. Following this social behaviour test, animals were pair housed in their
home cages with their original cage-mate. Analysis for social interaction used animal
pairs as subjects (VEH: Male n=8, Female n=8; LPS: Male n=8, Female n=7; 5VEH:
Male n=7, Female n=9; PPA: Male n=8, Female n=8).
Locomotor activity of each animal was measured (total distance, movement time,
velocity, vertical time). Social behaviour was quantified using the automated measures of
the average distance between pairs of animals in cm, and the time animals spent within 5
cm proximity of each other. Manual scoring of social behaviour for each animal was
carried out according to previously described criteria (Pellis et al., 1997):
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1. Frequency of social initiations: number of snout to nape contacts.
2. Probability of defense: the number of defenses performed by an animal (withdrawal of
the nape from the partner’s snout) divided by the number of social initiations performed
by the partner towards that animal.
3. Type of defense: i) Probability of facing defense: the number of facing defenses
(withdrawal of the nape from the partner’s snout by turning to face the partner) divided
by the total number of defenses times 100. ii) Probability of evasive defense: the number
of evasive defenses (withdrawal of the nape from the partner’s snout by either running or
turning away from the partner) divided by the total number of defenses times 100.
A second experimenter manually scored a subset of the data in order to calculate interrater reliability using Pearson correlations (15 pairs, 30 animals).
4.2.3.3. Novel object vs. Novel rat choice test, P42
Rats were re-habituated to the open-field arena without any bedding on P39-41
for 5 min each. On P42, a novel object vs. novel rat directed behaviour test was
conducted to assess social approach to a confined social animal (Choleris et al., 2009)
and to determine if prenatal LPS or PPA treated offspring would direct behaviour to an
inanimate object rather than a novel conspecific.
A novel sex, age, and weight-matched untreated stimulus rat was restrained in a
small cage with a circular Plexiglas top and bottom and a wire mesh cylindrical wall
(diameter, 18 cm; 1.0 cm wire mesh). The cage was large enough for the stimulus rats to
be able to turn around freely and rear, with the stimulus rats habituated to the cage and
open-field for 3 days prior to testing. No stimulus rat was used in more than 5 novel
object vs. novel rat choice tests. A small plastic children’s toy, approximately 5 cm x 7
cm x 8 cm, served as the novel object.
The caged novel rat and novel object were placed opposite each other in the
circular arena approximately 10 cm from the wall. Experimental rats were placed at the
centre of the arena midway between the novel object and the novel rat facing the wall.
Rats were tested one at a time for 5 min, and the arena and object were cleaned with an
alcohol–water solution after each rat. Each rat was tested once and the same object was
used for all of the tests, with the novel object/rat positions counterbalanced within litters.
The percent of time approaching the novel rat or the novel object (moving towards either
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stimulus while within 35 cm of stimulus) and total duration within 10 cm proximity of
the novel rat or the novel object were determined by the EthoVision software.
4.2.3.4. Novel object recognition, P43
In order to determine whether or not there was a general impairment in
recognition, a novel object recognition test was employed on P43. Two novel objects
(plastic children’s toys, 5 cm x 7 cm x 8cm) were placed in the open-field at opposite
ends, approximately 10 cm from the wall. Rats explored the open-field and the objects in
this 5 min exploration phase before being removed from the arena for 2 min. During this
time, one of the objects from the exploration phase was removed and replaced by a new
novel object so that one object was now familiar and one was novel. Rats were then
recorded for 5 min in this test phase. If recognition is intact, more time should be spent in
contact with the novel object as opposed to the familiar object (Choleris et al., 2009). The
same 3 objects were used for all of the rats, with object placement and novel object
identity in the test phase counterbalanced between and within litters. Objects were
cleaned with an alcohol-water solution after testing with each rat and between the
exploration and test phases. Manual scoring of each animal was performed. The time
spent in contact (s) with each of the 2 objects was measured in both the exploration and
test phase.
4.2.3.5. Adult social interaction test, P70
Animals were housed individually overnight (24 hr) before social interaction
testing took place in adulthood on P70. Animals were colored with a marker the day
before and immediately prior to the 15 min test with a partner in the arena. Pairings were
same-sex, same-prenatal drug, but as in adolescence, with a non-cage mate from the same
litter. Similar to adolescence, behaviour was recorded with the EthoVision software and
the same automated and manual behavioural measures were obtained.
4.2.4. Data analysis
All analyses were performed with IBM Statistics 20 (formerly Statistical Package
for the Social Sciences). As groups of rat pups belong to litters, they are not independent
samples and effects associated with being raised in a litter must be accounted for. To do
this, linear mixed models were used for each of the dependent variables, with Litter used
as a subject variable and litter size as a covariate. Fixed factors in most models were Sex
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and Prenatal drug. For body weight, nest seeking response, and habituation to the openfield, Week or Day was included as a fixed factor. A fixed factor of Stimulus type was
included in the models for the novel object vs. novel rat (2 levels: object and rat) and the
novel object recognition test (2 levels: one for each object). LSD post-hocs were
performed. Significance was set to

= 0.05.

4.3. Results
4.3.1. Body weight across lifespan
A significant Week x Sex interaction, F(10,1623) = 752.0, p < 0.001, showed that
for the first 3 weeks of life, males and females were not significantly different (Figure
4.1A-B). From P28 on, males weighed significantly more than females, ps < 0.001.
Additionally, there was a Week x Prenatal drug interaction, F(30,1623) = 4.62, p < 0.001.
There were no differences in body weight between prenatal groups for the first 5 weeks
of life. On P42 and P49, prenatal 5VEH treated animals weighed significantly more than
prenatal VEH treated animals, ps < 0.05. This was found for females on P42 (p = 0.041)
and males and females on P49 (ps < 0.05). On P49 (males) and P63 (males and females),
prenatal LPS treated animals weighed significantly more than prenatal VEH treated
animals, ps < 0.05. The last 2 weeks (P63, P70), prenatal PPA and 5VEH treated animals
weighed significantly more than prenatal VEH animals (ps < 0.01) in both males (ps <
0.05) and females (ps < 0.05).
4.3.2. Nest seeking behaviour (olfactory discrimination), P9-11
Latency to reach the home bedding was recorded across P9-11. There was a
significant effect of Day, F(2,602) = 15.60, p < 0.001, with all pups improving from P9
to P10 and taking significantly less time to reach their home bedding. There was no effect
of Sex and a significant effect of Prenatal drug, F(3,602) = 4.17, p = 0.006. Overall,
prenatal PPA treated offspring took significantly longer to approach and reach their home
bedding than either prenatal LPS or VEH, ps < 0.01 (Figure 4.1C). On P9, prenatal PPA
treated offspring took significantly longer to reach home bedding than all other prenatal
groups, ps < 0.05. Prenatal LPS treated offspring did not significantly differ from their
prenatal control treated offspring in nest seeking behaviour.
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Figure 4.1. Body weight and nest seeking response.
Rats were prenatally exposed to either lipopolysaccharide (LPS), propionic acid (PPA),
or their respective vehicle controls (VEH and 5VEH). Body weight was monitored
weekly. A: Males and B: Females. * p < 0.05: Prenatal 5VEH animals weighed
significantly greater than prenatal VEH animals; additionally, prenatal PPA animals
weighed greater on P63, 70. ^ p < 0.05: Prenatal LPS animals weighed significantly
greater than prenatal VEH.
C: Nest seeking response. Home and clean bedding were placed at opposite ends of a
small chamber. The time to reach home bedding by individual pups was measured (max.
score 180 s). Prenatal PPA treated offspring, regardless of sex, took significantly more
time to reach home bedding on P9 than all other prenatal treatment groups. * p < 0.05.
Error bars represent S.E.M. Further details of the prenatal treatments, sample sizes, and
statistical analysis are provided in the text.
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4.3.3. Open-field behaviour, P30-32
Total distance traveled and velocity showed similar patterns with both measures
decreasing across days, F(2,348) = 103.18, p < .001 and F(2,348) = 103.45, p < 0.001
(Figure 4.2A-B). Significant Sex x Prenatal drug interactions were found for total
distance F(3,349) = 4.51, p = 0.004, and velocity F(3,349) = 4.52, p = 0.004. While there
were no significant differences between prenatal treatments, there were sex differences
within treatments. In VEH treated animals, females traveled a significantly greater total
distance (p = 0.018) and with a greater velocity than males (p = 0.017), while in PPA
treated offspring, males traveled a significantly greater total distance (p = 0.018) and with
a greater velocity than females (p = .018). Movement time also showed a pattern of
decreasing activity across days, F(2,348) = 68.06, p < 0.001, with a significant Sex x
Prenatal drug interaction, F(3,349) = 2.96, p = 0.032. Again, PPA treated males spent
significantly more time moving than PPA treated females (p = 0.007), and LPS treated
males compared to females neared significance (p = 0.051, Figure 4.2C).
Vertical movements, or rearing, did not show any significant effects of prenatal
drug. Rearing on P30 was significantly greater than on P31 and 32, F(2,348) = 11.46,
p < 0.001 (data not shown), and females reared significantly more than males,
F(1,352) = 6.43, p = 0.012 (Figure 4.2D). Lastly, a significant effect of Day was found
for percent time in the centre of the open-field, F(2,348) = 13.02, p < 0.001. Animals
spent significantly more time in the centre on P30 than on P31 and 32. This likely reflects
that the starting position of the rats was the centre of the open-field (data not shown).
4.3.4. Social interaction test – Adolescence P33 and Adulthood P70
4.3.4.1. Adolescent social behaviour
On P33, there were no significant effects of prenatal drug on the distance between
pairs of animals or on time rats spent within 5 cm proximity of each other during the
social interaction test. There was however an effect of sex, as males spent significantly
more time within 5 cm of each other than did females, F(1,43) = 6.09, p = 0.018 (Figure
4.3A) and initiated interactions significantly more often than did females,
F(1,107) = 16.39, p < 0.001 (Figure 4.3B). There were no significant effects of prenatal
drug for initiations, or significant effects of sex or prenatal drug for probability of
defense, and probability of facing and evasive defense (Figure 4.3C-D). There was
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Figure 4.2. Locomotor activity in the novel open-field collapsed across days (P30-32) in
male and female rats.
A: Total distance traveled (cm), B: Velocity, and C: Movement time (s). Rats were
prenatally exposed to either lipopolysaccharide (LPS), propionic acid (PPA), or their
respective vehicle controls (VEH and 5VEH). Prenatal PPA treated male offspring were
significantly more active than prenatal PPA treated female offspring for all 3 measures,
while prenatal VEH treated female offspring traveled a greater distance than prenatal
VEH treated male offspring, ps < 0.05. D: Rearing. Female offspring reared significantly
more than male offspring, p < 0.05. Error bars represent S.E.M. Further details of the
prenatal treatments and sample sizes are provided in the text.
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Figure 4.3. Adolescent social behaviour on P33.
Rats were prenatally exposed to either lipopolysaccharide (LPS), propionic acid (PPA),
or their respective vehicle controls (VEH and 5VEH). A: Time animals spent within 5 cm
proximity to each other. Male offspring spent significantly more time within 5 cm
proximity to each other than female offspring, p < 0.05. B: Number of initiations,
C: Probability of defense once contact is initiated, and D: Type of defense: Facing or
evasive. Error bars represent S.E.M. Details of the prenatal treatments and sample sizes
are provided in the text.
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significant inter-rater reliability for manual scoring of adolescent social behaviour
(initiations r(28) = 0.88, p < 0.001; facing defense r(28) = 0.54, p < 0.01; evasive defense
r(28) = 0.81, p < 0.001).
4.3.4.2. Adult social behaviour
On P70, there were also no significant effects of prenatal drug or sex on the
distance between pairs of animals or on time the rats spent within 5 cm proximity of each
other (Figure 4.4A). Males again initiated more interaction than females, but the effect
was not significant, F(1,99) = 3.77, p = 0.055 (Figure 4.4B). A significant effect of
Prenatal drug for probability of defense, F(3,99) = 3.13, p = 0.029, showed that prenatal
PPA and prenatal LPS treated animals engaged in defense significantly less than prenatal
VEH treated animals, ps < 0.05 (Figure 4.4C). There were no significant differences
between prenatal PPA and 5VEH (p = 0.330) or VEH and 5VEH (p = 0.128). Probability
of facing and evasive defense did not show any significant sex or prenatal drug
differences (Figure 4.4D). There was significant inter-rater reliability for manual scoring
of adulthood social behaviour (initiations r(28) = 0.89, p < 0.001; facing defense r(28) =
0.63, p < 0.01; evasive defense r(28) = 0.76, p < 0.001).
4.3.4.3. Locomotor activity during social interaction
During the social interaction test on P33, there were no significant effects of
prenatal drug and no sex differences in the total distance traveled and the number of
vertical movements. There was no effect of prenatal drug on movement time, but a
significant effect of Sex, F(1,107) = 7.60, p = 0.007, with male adolescent offspring
spending significantly more time moving than females. On P70, there were significant
effects of sex for total distance traveled, F(1,100) = 13.64, p < 0.001, and movement
time, F(1,109) = 46.67, p < 0.001, with females moving significantly more than males. A
significant Sex x Prenatal drug interaction for number of vertical movements,
F(3,100) = 2.77, p = 0.045, showed that female rats performed significantly more vertical
movements in the prenatal PPA, VEH, and 5VEH groups (ps < 0.05), but not in the
prenatal LPS group (data not shown).
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Figure 4.4. Adult social behaviour on P70.
Rats were prenatally exposed to either lipopolysaccharide (LPS), propionic acid (PPA),
or their respective vehicle controls (VEH and 5VEH). A: Time animals spent within 5 cm
proximity to each other, B: Number of initiations, C: Probability of defense once contact
is initiated, and D: Type of defense: Facing or evasive. Prenatal LPS treated animals,
collapsed across sex, engaged in defensive behaviour significantly less than prenatal
VEH treated animals, p < 0.05. Error bars represent S.E.M. Details of the prenatal
treatments and sample sizes are provided in the text.
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4.3.5. Novel object vs. Novel rat choice – P42
There was a significant effect of Stimulus type, F(1,239) = 6626, p < 0.001, as all
of the animals spent significantly more time within 10 cm of the novel rat compared to
the novel object. Females in the prenatal 5VEH treated group spent significantly less time
within 10 cm of the novel rats than did the prenatal PPA treated females (p = 0.023) and
prenatal 5VEH treated males (p < 0.001), Stimulus type x Sex x Prenatal drug
F(3,239) = 3.33, p = 0.020 (Figure 4.5A).
Percent time approaching the novel rat or novel object also revealed that all of the
animals spent significantly more time approaching the novel rat, Stimulus type
F(1,239) = 2898, p < 0.001. A significant Stimulus type x Sex x Prenatal drug
interaction, F(3,239) = 2.87, p = 0.037, showed that prenatal PPA treated males spent
significantly more time approaching the novel object compared to prenatal 5VEH treated
males, p = 0.009 (Figure 4.5B). A sex difference in the prenatal 5VEH group showed that
5VEH treated females spent significantly more time approaching the novel object than
did the males, p = 0.021.
4.3.6. Novel object recognition – P43
There was no significant sex or prenatal drug effect on the initial exploration of
the objects. The rats made a similar number of visits to, and spent a similar time
exploring, the objects. In the novel object recognition test, animals spent significantly
more time in contact with the novel object compared to the familiar object,
F(1,224) = 69.26, p < 0.001, regardless of prenatal drug. However, females made
significantly more visits to the objects (F(1,225) = 7.65, p = 0.006) and spent
significantly more time in contact with the objects than did males, F(1,225) = 6.52, p =
0.011 (Table 4.1).
4.4. Discussion
These results demonstrate that prenatal exposure to low levels of either PPA or
LPS has selective and sexually dimorphic effects on neonatal, adolescent, and adult
behaviour. Prenatal PPA treated male and female rats displayed delayed olfactory
mediated nest seeking behaviour. Male adolescent PPA treated rats displayed increased
approach to a novel object and enhanced novel open-field activity, without any changes
in social interaction. There were also no evident or significant effects of PPA on adult
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Figure 4.5. Novel Object vs. Novel Rat choice test on P42.
Rats were prenatally exposed to either lipopolysaccharide (LPS), propionic acid (PPA),
or their respective vehicle controls (VEH and 5VEH). A. Time spent within 10 cm
proximity to the stimuli, and B. Percentage of time spent moving towards either stimulus.
All animals spent more time near and more time approaching the novel rat. Prenatal
5VEH treated female offspring spent significantly less time near the novel rat than
prenatal PPA treated females. Prenatal PPA treated male offspring spent significantly
more time approaching the novel object than prenatal 5VEH treated males. * p < 0.05,
** p < 0.01 Error bars represent S.E.M. Further details of the prenatal treatments and
sample sizes are provided in the text.
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Table 4.1. Time spent at, and number of visits to, objects in the novel object recognition
test on P43 by male offspring (M) and female offspring (F) prenatally exposed to either
lipopolysaccharide (LPS), propionic acid (PPA), or their respective vehicle controls
(VEH and 5VEH). Further details of the prenatal treatments, sample sizes, and statistical
analysis are provided in the text.

Prenatal treatment
5VEH
LPS
6.85 ± .94 s
6.22 ± .81 s
6.35 ± .86 s
5.59 ± 1.26 s

TimeFamiliar

(M)
(F)

PPA
5.12 ± .77 s
6.44 ± .74 s

VEH
4.13 ± .52 s
5.83 ± .96 s

TimeNovel

(M)
(F)

9.40 ± 1.58 s
11.31 ± 1.19 s

8.85 ± 1.18 s
11.89 ± 1.32 s

8.84 ± 1.08 s
9.90 ± 1.38 s

7.29 ± .78 s
10.22 ± 1.25 s

# VisitsFamiliar

(M)
(F)

6.50 ± .98
6.94 ± .70

6.27 ± .52
6.83 ± .72

7.80 ± .83
6.86 ± 1.04

6.69 ± .65
9.0 ± .92

# VisitsNovel

(M)
(F)

5.44 ± .88
7.75 ± .62

6.60 ± .72
7.67 ± .62

7.13 ± .82
7.50 ± .86

7.06 ± .67
9.63 ± .75
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social behaviour. In contrast, although prenatal LPS did not influence social behaviour in
neonatal and adolescent rats, in adulthood, it decreased the probability that male and
female rats engaged in defensive behaviour. Taken together, these results suggest that
prenatal exposure to low levels of PPA and LPS produces subtle and sexually dimorphic
alterations in social and related behaviour with prenatal PPA having a greater impact on
neonatal and adolescent behaviour.
4.4.1. Nest seeking behaviour (olfactory discrimination)
As maternal separation has adverse consequences for rats, it is necessary for pups
to be able to recognize and respond appropriately to the olfactory cues of the home nest.
Consistent with this, and with the results of previous studies (Roullet et al., 2010;
Schneider and Przewlocki, 2005), vehicle treated male and female rats showed a rapid
discrimination and approach to maternal nest bedding.
Prenatal PPA increased the latency of male and female pups to reach home
bedding in the nest seeking response test, consistent with findings from animals receiving
prenatal VPA showing an increased time to find the home bedding (Roullet et al., 2010;
Schneider and Przewlocki, 2005). The present results may reflect decreased interest in the
social odors of the maternal nest and/or increased perseverance towards the clean odor.
Interestingly, adult male rats that received central PPA persevered at a location where
soiled bedding from the home cage of an unfamiliar rat had been placed and did not
investigate novel bedding (MacFabe, 2012; Meeking et al., unpublished). This, coupled
with nest seeking behaviour, may be interpreted as PPA-induced impairment, either in the
recognition, or utilization, of socially relevant olfactory cues. However, it cannot be ruled
out that prenatal PPA treatment may have influenced development of the olfactory
system.
Prenatal LPS had no significant effect on the latency to reach home bedding in the
test. This is contrary to a previous report reporting increased latency in nest seeking
response with prenatal LPS (Baharnoori et al., 2012). This discrepancy likely reflects
differences in timing and dose of LPS, as LPS exposure in this study is earlier in
gestation, and of a lower dose (50 vs. 100 g) than that used in Baharnoori et al. (2012).
The alteration in nest seeking response behaviour of pups receiving prenatal PPA
was not associated with any significant consistent changes in growth. During one week
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for males and two weeks for females, prenatal LPS treated animals were heavier. Results
of other studies have reported decreased, or no change in, body weight (see Patterson,
2011). This likely reflects dose and strain effects. However, the number of injections
received in gestation affected growth, suggesting that stress associated with injections
may have a developmental effect. Repeated vehicle injections can alter baseline levels of
plasma corticosterone (Drude et al., 2011), similar to chronic stress protocols (Weinstock,
2001). Rats born to dams treated with prenatal PPA or 5VEH control were heavier as
adolescents and adults than those born to dams treated with one injection of VEH.
Prenatal stress has been shown to result in heavier adult weights in mice (Mueller and
Bale, 2006) and decrease propensity for social interactions (Weinstock, 2001). Effects
associated with number of prenatal injections have also been seen in open-field activity
and an acoustic startle paradigm (Chapter 2, 3). The stress response associated with saline
injections, although mild in comparison to maternal stress paradigms, may have limited
the detection of some subtle effects of PPA.
4.4.2. Social behaviour and the effects of prenatal PPA and LPS
There were sex-specific changes in basal locomotor activity during habituation to
the open-field. Previous work has shown that adolescent and adult female rats generally
are more active than male rats (Lynn and Brown, 2009). However, in prenatal PPA
animals, adolescent males were more active than females, suggesting that prenatal PPA
may have increased activity in males, or possibly decreased activity in females.
Previously, central administration of PPA has induced hyperactivity in adult male rats
(MacFabe et al., 2007; Thomas et al., 2012), but female activity has not been
investigated. In contrast, prenatal LPS did not have any evident effects on adolescent
basal activity.
Consistent with the results of previous studies in adolescent rats, males engaged
in more social behaviour than females, as measured by time animals spent in proximity to
each other and in the number of social initiations (Olioff and Stewart, 1978). The higher
incidence of social play in males may also account for the sex difference in adolescent
locomotor activity during behavioural interaction. In adulthood, there was no sex
difference in social interaction, although sex differences in social initiations approached
significance. Social play activity peaks in adolescence (Thor and Holloway Jr., 1984),
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making differences in adulthood less likely, although overall males are still generally
more likely to engage in social interaction. This may also be reflected in the greater
locomotor activity displayed by females.
Prenatal LPS and PPA did not significantly affect social interactions in
adolescence as measured in a paired interaction test of social play. Results of previous
MIA studies using the viral mimetic, poly I:C, and LPS have reported reduced social play
in adolescent males (see Patterson, 2011). This difference may again be attributed to the
relatively low doses of LPS and PPA as well as differences in the timing of
administration.
Evidence of subtle alterations in adolescent social behaviour with prenatal PPA
was however present in the novel object vs. novel rat choice test. Prenatal PPA
adolescent males spent significantly more time approaching the novel object than
corresponding vehicle treated males, suggesting a subtle alteration and decrease in social
preference. This increased interest in the novel object is similar to the decrease in social
approach to an unfamiliar mouse relative to a non-social object in a 3 chamber apparatus
seen in VPA and MIA mice (Kim et al., 2013; Smith et al., 2007). Taken together with
the delay in nest seeking response in prenatal PPA offspring, it is possible that odor
associated with the novel rat may not have been as salient of a social cue leading to
changes in social responses. Interestingly, in a similar task, adolescent males receiving
central PPA spent less time in proximity to, and less approach behaviour towards, the
novel rat (MacFabe et al., 2011). This effect in prenatal PPA males is also consistent with
the male predominance seen in ASD.
In the novel object recognition task, all adolescent animals spent more time
investigating the novel object, with female rats spending more time than males in total
contact with the objects, consistent with prior studies (Howland et al., 2012). As well,
there was no effect of prenatal treatment, again consistent with prior MIA studies
(Howland et al., 2012; Mychasiuk et al., 2012). While novel object recognition confirmed
intact recognition abilities for non-social items, it does not necessarily rule out the
possibility of an alteration in the recognition of novel conspecifics.
In adulthood, once social interactions were initiated, although prenatal LPS
treated male and female rats spent a similar amount of time near each other as control
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rats, they showed a decrease in the probability to engage in defensive behaviour (effect
collapsed by sex). Decreased defensive behaviour could be interpreted as an indifference
of the animals towards the social partner. This change in defensive behaviour may be
associated with prenatal LPS-induced alterations in dopaminergic activity which has been
shown to influence defensive behaviour (Baharnoori et al., 2013).
Prenatal PPA did not significantly alter social interaction between pairs of
animals in adulthood (P70). It should be noted that prenatal PPA treated rats displayed a
significant decrease in defensive behaviour relative to the VEH group, similar to LPS.
However, repeated VEH injections (5VEH) also non-significantly decreased defensive
behaviour, potentially attenuating or masking the effects of PPA. Previous work in adult
male rats has demonstrated that central PPA can rapidly decrease social behaviour
(Shultz et al., 2008). However, the effects of acute PPA treatment and prenatal PPA are
not necessarily comparable.
Previous MIA studies used higher doses of immune stimulants while the current
study used a low dose of LPS (50 g vs. 100 g). Studies of neonatal LPS using a similar
dose as this study produce a number of sexually dimorphic behaviours, including
increased anxiety-like behaviour and altered responses to adult immune challenges (Tenk
et al., 2008; Walker et al., 2009). Although milder effects of prenatal LPS on social
behaviour were seen here, this does not necessarily exclude alterations in
neurodevelopment. Manipulations in development may leave animals susceptible to later
environmental insults. Neonatal LPS enhanced hypoactivity to an immune challenge in
adulthood, while neonatal LPS combined with restraint/isolation stress in adulthood
decreased locomotor activity and increased anxiety-like behaviour (Tenk et al., 2008;
Walker et al., 2009). Prenatal immune activation may act to predispose individuals to a
number of neuropsychiatric conditions, or act on pre-existing genetic predispositions
(Patterson, 2011). While the current dose of LPS did not directly influence social
behaviour in adolescent rats and minimally affected adult behaviour, it is possible that a
second environmental stressor is required for changes in social and other behaviour to be
expressed.
Similar to LPS, a low dose of PPA was administered in this study to represent
subchronic changes in the gut microbiome. PPA is endogenous and very quickly
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metabolized, and this may have contributed to the subtle alterations in behaviour. It is
possible that prenatal PPA treated rats are susceptible to further environmental trauma.
An additional insult in adolescence or adulthood may have allowed for further
behavioural changes to manifest. A combination of prenatal and postnatal PPA sensitized
acoustic startle responses in female adolescent rats (Chapter 3), consistent with prenatal
immune activation predisposing rats to further environmental insults.
4.4.3. Relation to autism spectrum disorders
ASD include altered neural synapse maturation and connectivity, leading to a
possible imbalance between inhibition and excitation (MacFabe, 2012). Immune
dysregulation in patients with ASD suggests the presence of an inflammatory state and
maternal infection as a risk factor. Prenatal LPS, as mentioned, alters dopaminergic
functioning in offspring and has also been shown to decrease the number of GABAergic
neurons in adult animals (Nouel et al., 2012). These and other changes in
neurotransmission may occur via increases in proinflammatory cytokines altering gene
expression involved in neural migration of inhibitory interneurons or the developmental
processes itself (Garbett et al., 2012; MacFabe, 2012).
PPA may alter neurotransmission via epigenetic developmental changes in gene
expression through histone deacetylation of ASD implicated genes (Nguyen et al., 2007),
similar to that suggested for valproic acid (D'Souza et al., 2009; Phiel et al., 2001). As
well, PPA has specific G-protein coupled receptors and can have adverse effects on
oxidative stress and decrease neurotransmitter levels such as GABA, serotonin, and
dopamine (MacFabe et al., 2007; MacFabe, 2012). PPA and other SCFAs are part of gut
functioning and under normal conditions serve a variety of physiological and immune
functions. However, shifts in the composition of the microbiome may lead to augmented
and inappropriate levels of PPA that could have adverse effects (Al-Lahham et al., 2010).
In conclusion, prenatal exposure to low levels of PPA subtly altered social
behaviour in neonatal and adolescent rats in a sex-specific manner, while a low dose of
LPS altered social behaviour in adult male and female rats. Repeated infection or immune
insult throughout gestation and early life may influence the gut microbiome and provide
an enteric environment that promotes the overgrowth of certain bacteria, leading to

127

production of metabolic products, such as PPA or LPS, which may adversely alter
neurodevelopment.
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Chapter 5
General Discussion
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The effects of prenatal and postnatal administration of the microbiome bacterial
metabolic products, PPA and LPS, on development and behaviour of male and female
rats were examined. Additionally, PPA was administered in the second week of life to
determine if a postnatal insult would exacerbate any behavioural effects. The relatively
subtle, sex-specific, and treatment-specific alterations in behaviour found are summarized
in Table 5.1. The developmental delay, altered locomotor activity, sensory responses, and
social behaviour found in adolescent male and female rats resembled previous animal
models and features of human ASD, suggesting metabolic products of enteric bacteria
may contribute to the development of ASD.
5.1. Developmental milestones
Assessment of milestones and body weight provided a gross measure to determine
if prenatal and postnatal drug treatments affected neurodevelopment and general health.
Minimal consistent effects on body weight were observed. Developmental delay in eye
opening (Chapter 2) in both males and females receiving prenatal PPA or LPS and delay
in acquisition of odor mediated nest finding (Chapter 4) in males and females receiving
prenatal PPA was observed in the first 2 weeks of neonatal life. The developmental
delays see here point to an impact of early infection on socially related factors.
Additionally, the free fall righting reflex of female pups was impaired with a combination
of prenatal LPS and postnatal PPA. A delay in eye opening and motor reflexes have been
reported in the VPA animal model of ASD (Roullet et al., 2010; Schneider and
Przewlocki, 2005; Wagner et al., 2006). Developmental delay is observed within the first
12-24 months of life in infants with ASD or high risk siblings and may include delays in
gesturing or language (Filipek et al., 1999; Mitchell et al., 2011). Infants may also display
postural instability, head lag, hypotonia and/or delay in walking (see Mitchell et al., 2011
for review).
5.2. Locomotor activity and anxiety-like behaviour
Minimal changes in total locomotor activity were seen after prenatal treatment
with PPA or LPS. However, males receiving prenatal PPA were more active than females
receiving PPA (Chapter 4), opposite to what was observed in vehicle control animals.
Repetitive behaviour in females was observed with the combination of pre- and postnatal
PPA, consistent with the double-hit hypothesis (Chapter 2). These results suggest, again,
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Table 5.1. Summary of significant effects of either prenatal LPS, pre-, or postnatal PPA on subsequent offspring behaviour
Neonatal
Pre-PPA

Body Weight
Adolescent

Eye
Opening

Adult

+

M

+
+
ND
ND

F
Post-PPA

+
-

M
F

EPM
Open
Pre-PPA

+

EPM
Closed

M
F

Pre-LPS

M

Post-PPA

M

-

+

F
F

+

Initial

+
+
+
+
+

Reflex

O/F
Activity

-

M
F

Pre-LPS

Milestones
Physical

ASR
Habituation

Average

%PPI

Nest Seeking
Latency

-

+
+

O/F Centre
Time

O/F Centre
Activity

-

+
+

Social
Adolescent

+
-

ND
ND

Social
Approach

NOR

-

+
-

interaction
Adult

ND
ND

ND
ND

ND
ND

ND
ND

M- Males, F- Females. + denotes increase in behaviour, - denotes decrease in behaviour compared to vehicle control offspring.
Empty space denotes no effect of drug, ND = not determined.
Pre-PPA: PPA administered on G12-16, 500 mg/kg SC; Pre-LPS: LPS, 50 g/kg SC, administered on G12-16, or G12 (social
measures, last 5 columns); Post-PPA: PPA administered 2x/day, every other day, P10-18, 500 mg/kg SC
Physical Milestones: top and bottom incisor eruption and pinna detachment. Reflex Milestones: righting reflex, negative geotaxis,
free-fall righting reflex
O/F- open-field, EPM- elevated plus maze open and closed arm time, ASR- acoustic startle response, %PPI- percent prepulse
inhibition, NOR- novel object recognition
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that PPA produces subtle and sexually dimorphic changes in activity.
Both hypo- and hyperactivity are reported in ASD. Hyperactivity and a range of
repetitive or restricted behaviours are observed throughout childhood. MIA rodent studies
report restricted behaviours, with decreased exploratory behaviour in an open-field
(Malkova et al., 2012; Smith et al., 2007), while VPA studies report decreased
exploration and hyperactivity, although this is not always the case (Schneider and
Przewlocki, 2005; Mychasiuk et al., 2012). Decreased exploratory behaviour was
observed in both male and female rats receiving prenatal PPA (decreased open-field
centre time), but there was limited evidence supporting hyper- or hypoactivity. Prenatal
PPA, LPS, and postnatal PPA alone did not alter locomotor activity in a small open-field
(Chapter 2). In Chapter 4, a large open-field arena was used and males receiving prenatal
PPA were more active than females receiving prenatal PPA, opposite to what was
observed in vehicle controls. Lastly, increased repetitive behaviour (number of
revolutions) in females receiving a double hit of prenatal and postnatal PPA provided
evidence for a double hit hypothesis (Chapter 2). Increased repetitive behaviour specific
to females has been observed in the VPA rodent model (Schneider et al., 2008). This
indicates that locomotory effects are dependent on the measures used, suggesting
interactions with other environmental/experiential factors.
Both male and female adolescents prenatally exposed to PPA showed an increase
in anxiety-like behaviour in the open field and pre- and postnatal PPA produced an
increase in anxiety in females in the EPM (Chapter 2). Anxiety is one of the most
common psychiatric disorders that occurs comorbidly with ASD (Skokauskas and
Gallagher, 2010). Additionally, anxiety and depression are commonly seen with GI
dysfunction (Donner and Lowry, 2013). Previous studies with MIA report increased
anxiety-like behaviour in adult offspring, with limited and conflicting reports in
adolescence (Enayati et al., 2012; Schwendener et al., 2009; Smith et al., 2007). The
current results support a role for prenatal and postnatal PPA in contributing to anxietylike phenotypes. Enhanced behaviour to threatening situations may be analogous to
atypical affective responses seen in children with ASD (e.g., inappropriate emotional
response, increased neutral expressions) (Mitchell et al., 2011; Zwaigenbaum et al., 2005)
and as such consistent with the present results.
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5.3. Sensitivity to acoustic stimuli and sensorimotor gating (Chapter 3)
Hyper- and hypo-sensitivity to environmental stimuli and difficulties with
habituating to repeated stimuli have been reported in patients with ASD, with some
evidence of decreased prepulse inhibition (Leekam et al., 2007; Ornitz et al., 1993; Perry
et al., 2007). Consistent with these observations in humans, prenatal PPA, prenatal LPS,
and postnatal PPA altered acoustic startle response behaviour in male and female
adolescent rats. Effects were subtle and short-lived, as animals displayed abnormal
responses to the initial startle pulse and then adjusted responding.
Prenatal LPS did not alter prepulse inhibition. This is contrary to previous MIA
studies in adolescent and adult rats (Howland et al., 2012; Fortier et al., 2007). Robust
hypersensitivity to startle in males was seen over the course of a startle session similar to
Fortier et al. (2004), providing a dissociation of aberrant startle responses and
sensorimotor gating with a low dose of LPS. Prenatal LPS did not affect habituation to
the acoustic stimuli. On the other hand, postnatal PPA in males, and the combination of
prenatal and postnatal PPA in females, produced sensitization (hypersensitivity) rather
than habituation to the startle pulses over the first 2 sessions. With repeated exposure
over days, all animals habituated in a similar manner to control animals. In one report,
adults with ASD took longer to reach the same level of habituation to acoustic stimuli as
other adults and (Perry et al., 2007), with evidence of decreased habituation to auditory
sounds in at risk infants and males with Fragile X syndrome (Guiraud et al., 2011; Van
der Molen et al., 2012). Similar to decreases in prepulse inhibition observed in MIA and
VPA studies (Howland et al., 2012; Schneider and Przewlocki, 2005), decreases in
prepulse inhibition were observed in female rats receiving prenatal PPA and in male and
female rats receiving postnatal PPA. The current results indicate that PPA and LPS
administration in development can alter sensory processing in ways that may resemble
behaviours seen in ASD.
5.4. Social and related behaviours
Altered social behaviour is one of the core behavioural deficits in ASD (DiCiccoBloom et al., 2006; Zwaigenbaum et al., 2005). Impaired social behaviour has been
observed in rodents in social interaction tests and social approach tests in both MIA and
VPA models. Chapter 4 assessed social behaviour in rat offspring following prenatal PPA
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or prenatal LPS using a social interaction test and social approach to a novel object
versus to that of a novel rat. In addition, olfactory mediated nest seeking behaviour in
neonatal rats was measured and prenatal PPA treated male and female neonatal rats were
delayed in reaching home bedding. This is consistent with VPA studies (Roullet et al.,
2010; Schneider and Przewlocki, 2005) and may suggest a social impairment in
recognizing or using socially relevant cues in very young animals.
Prenatal PPA did not alter paired social interaction in adolescent or adult rats.
However, evidence of alterations in social approach was seen in adolescent male rats,
with more time spent approaching the novel object than vehicle controls. This subtle
effect resembles that seen in MIA and VPA studies using the 3 chamber apparatus where
treated animals spend more time in a chamber containing a non-social object compared to
a chamber containing a conspecific, or more time in an empty chamber compared to
controls (Dufour-Rainfray et al., 2010; Malkova et al., 2012; Smith et al., 2007). The
current study provides some evidence supporting prenatal PPA producing behaviours that
resemble ASD. The absence of PPA effects in social interaction may be due to drug
administration (discussed below) or alternatively, a 3 chamber apparatus or test of novel
social recognition may more effectively parse out any effects of PPA.
Prenatal LPS did not alter social behaviour in neonatal or adolescent rats;
however, in adulthood, decreased social behaviour (decreased probability to engage in
defensive behaviour) was observed. Previous MIA studies with the viral mimetic, poly
I:C, have shown decreased social behaviour in mice (Smith et al., 2007) and Taylor et al.
(2012) report LPS-induced decreases in social interaction and play behaviour in
adolescent rats. The results observed in the current study may be explained by the earlier
administration of LPS and the lower dose of LPS used here compared to other studies
(Oskvig et al., 2012; Taylor et al., 2012). Overall, changes in social behaviour are
consistent with decreases observed in previous animal studies and in ASD.
5.5. Evidence for the double-hit hypothesis
PPA was administered during the second postnatal week to act as a double ‘hit’.
The double hit hypothesis describes that a genetic predisposition or environmental insult
early in life may confer vulnerability to an environmental trigger later in life that results
in emergence of adverse behaviour or neuropathology (Bayer et al., 1999). In humans,
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adverse childhood experiences have been associated with an increased susceptibility to
psychopathology such as mood disorders and altered stress responses (Heim and
Nemeroff, 2001; McGowan et al., 2009). Evidence for the double-hit hypothesis was
found in female rats, but not male rats. The combination of prenatal and postnatal PPA
altered behaviour in females where individual drug treatments alone did not. Repetitive
behaviour and sensitization to acoustic startle was present in female rats, but not males.
The free-fall righting reflex was also impaired in females receiving a combination of
prenatal LPS and postnatal PPA. This is similar to a previous MIA study where a stress
protocol in adolescence manifested MIA-induced alterations in behaviour similar to that
seen in schizophrenia and autism (Giovanoli et al., 2013). Children with ASD were found
to have had a greater number of ear infections and to use more antibiotics than typically
developing children (Niehus and Lord, 2006), suggesting a circumstantial link to repeated
early life insults and immune activation.
5.6. Sex differences: Females may be more susceptible to the effects of PPA
The prevalence of ASD favors males, with 4 males to every 1 female diagnosed
with ASD. Prenatal PPA influenced the approach to a novel object and prenatal LPS
produced hyper-sensitivity to acoustic startle in male, not female, adolescents, coinciding
with the idea of male predominance in ASD. However, prenatal and postnatal PPA and
prenatal LPS influenced male and female offspring behaviour in similar ways for many
behaviours measured. Furthermore, female offspring were more sensitive to the effects of
prenatal and postnatal PPA as both treatments combined produced sensitization to
acoustic startle and increased repetitive movements. Additionally, pre- and postnatal PPA
decreased sensorimotor gating and increased anxiety on the EPM in females that was not
observed in males.
These behavioural results in females may relate to phenomena observed in human
ASD. Females may be under-diagnosed due to differences in normal coping behaviour
and social communication skills compared to males. Girls that display high scores on
autistic traits similar to that of boys are nevertheless diagnosed less frequently than boys
(Russell et al., 2011). When females are diagnosed with ASD, they are more severely
affected and often intellectual disability brings attention to the behavioural symptoms
(Fombonne, 2009; Russell et al., 2011). Females are likely to show more repetitive
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interests, sensory symptoms, and display emotional symptoms such as anxiety or
depression (Lai et al., 2011; Mandy et al., 2012). Acquired metabolic dysfunction in
mitochondria has been suggested to contribute to ASD symptoms; a more balanced male
to female ratio and presence of gastrointestinal abnormalities were significantly greater in
children with ASD and mitochondrial disease (MD) as opposed to ASD or MD alone
(Rossignol and Frye, 2012). PPA may interfere with mitochondrial metabolism, inducing
oxidative stress and disrupting fatty acid oxidation (Frye et al., 2013; MacFabe et al.,
2008).
It is possible then, that the sex ratio observed in studies may reflect the nature of
the environmental toxin, with a certain sex more vulnerable to particular toxins. VPA
studies have shown male-specific behavioural effects, while MIA studies have not shown
many sex differences. There is, however, evidence that adult females may be more
vulnerable to the effects of drug abuse (Fattore et al., 2008), suggesting sex-specific
alterations in neurochemical systems. Adult female rats are more sensitive to the
reinforcing effects of stimulants (Lynch, 2006). Neonatal LPS increased the development
of dopaminergic locomotor sensitization in female, but not male, rats (Tenk et al., 2007),
while altering neophobia in both males and females (Tenk et al., 2013). As such, it is
possible that SCFAs and PPA may affect males and females similarly for some
behaviour, with either a greater female or male susceptibility for other behaviours. The
behavioural data of the current studies tentatively support this hypothesis, though further
investigation is needed.
5.7. Potential mechanisms for alterations in neurodevelopment
Short-term LPS and PPA administration during prenatal and early life may have
the capacity to alter neurodevelopmental processes leading to changes in brain and
behaviour later in life. SCFAs may gain access to the developing fetus through active
transport via monocarboxylate transporters in the placenta (Nagai et al., 2010), while
immune stimulants may exert effects via cytokines; for example, through IL-6 activation
of intracellular pathways in the placenta (Hsiao and Patterson, 2011; Shi et al., 2005).
An ongoing innate neuroinflammatory state may contribute to ASD as postmortem study of brains of ASD patients show increased astrocytes, activated microglia,
and cytokines (Li et al., 2009; Vargas et al., 2005). Microglia are present in rodent brain
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from about G13-14 and have been shown to play a role in neurodevelopmental processes
such as cell differentiation and synapse pruning. Cytokine release from microglia could
perpetuate a chronic inflammatory response throughout life, with sensitized responding to
environmental insults (see Bilbo and Schwarz, 2012; Deverman and Patterson, 2009).
Increases in proinflammatory cytokines have been detected in the amniotic fluid and the
fetal brain following LPS treatment (Gayle et al., 2004; Ning et al., 2008) with some
evidence suggesting that PPA may also be capable of inducing a neuroinflammatory
response and cytokine release (El-Ansary et al., 2011; Foley et al., 2008; MacFabe et al.,
2007). Elevated IL-6 has been hypothesized to contribute to the excitatory/inhibitory
imbalance in neuronal circuits that might contribute to ASD (Rubenstein and Merzenich,
2003; Wei et al., 2013).
Epigenetic mechanisms present a plausible mechanism for how environmental
toxins or insults in early fetal or neonatal life could lead to altered neurotransmission
and/or circuitry and delayed manifestation of behavioural impairments as children
develop. Epigenetic involvement, that is, changes to chromatin structure without altering
the genetic sequence, is being recognized as contributing to ASD. Modifications to genes
results in increased or decreased gene expression. For example, a recent post-mortem
brain analysis of ASD patients identified novel methylation sites in the temporal cortex
and cerebellum that were modified compared to non-ASD brains. These sites may be
involved in immune and mitochondrial functions (Ladd-Acosta et al., 2013). Patients
with known epigenetic disorders, such as Rett syndrome or Fragile X syndrome, often
have autistic features and can be diagnosed on the autism spectrum (Grafodatskaya et al.,
2010).
VPA and PPA are both histone deacetylase inhibitors, placing them in a position
to effect epigenetic change through alterations in gene expression (Nguyen et al., 2007;
Phiel et al., 2001). Thus far, studies have shown that VPA can interfere with neural
migration and cell differentiation via the Wnt signalling pathway (Go et al., 2012; Wiltse,
2005). Preliminary results have shown that central administration of PPA can alter gene
expression in ASD associated genes (Nankova et al., 2012). Prenatal LPS administration
has also been shown to alter expression of genes involved in neural migration and
neurotransmission (Oskvig et al., 2012).
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5.8. Relation to PPA rodent model of ASD
As discussed in Chapter 1, results of previous studies have shown central and
peripheral administration of PPA produce changes in behaviour, including hyperactivity
and decreased social interaction, and neuropathological and metabolic changes in adult
and adolescent male rats similar to that seen in ASD (reviewed in (MacFabe, 2012). The
current results add to the face validity of this model by demonstrating that PPA
administered during development can produce changes in the behaviour of rat offspring
in ways that resemble ASD. It remains to be seen if PPA administered early in
development induces neuropathological or metabolic changes similar to those seen
following either central PPA or in ASD.
I hypothesized that PPA would alter behaviour in rat offspring in similar ways to
that observed in other developmental models (VPA, MIA). Changes in behaviour with
prenatal PPA, prenatal LPS, and postnatal PPA were subtle and even transient in some
cases. Given that PPA is endogenous, metabolized fairly quickly, and was administered
in healthy animals, the load may not have been sufficient to cause large functional
changes in behaviour. It is unknown what amount of PPA is reaching the offspring in
utero. Likewise, many behavioural results of prenatal LPS administration were not
similar to past MIA studies. This may be due to the low level of LPS used in the present
studies. It was important to first characterize the effect of prenatal administration of PPA
and LPS before extending the work to multiple prenatal insults. There was limited
evidence for the double hit hypothesis, with postnatal PPA combined with prenatal PPA
or prenatal LPS altering behaviour in a couple of instances not otherwise seen with each
treatment alone. Again, creating an experimental situation that is more naturalistic, such
as combining SCFA or inducing colitis may alter the behavioural results observed.
5.9. Conclusions
In summary, my thesis provides a broad overview of the effects of pre- and
postnatal PPA, and prenatal LPS administration on the behaviour of male and female rats.
The emphasis of these studies on adolescent rat behaviour in both males and females add
to the literature that exists on the topic and is important given the developmental and
sexually dimorphic nature of ASD. Subtle and sex-specific effects on locomotor, anxiety,
sensory, and social behaviour were observed, providing evidence that metabolic products
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of enteric bacteria may alter development in ways resembling ASD. The different
behavioural phenotypes for the different administrations of PPA and LPS illustrate how
environmental insults may produce a range of symptoms on the autism spectrum,
depending on developmental timing. Furthermore, the effects of PPA and LPS may not
be limited to modelling ASD symptoms. Risk factors and behaviours associated with
neurodevelopmental disorders such as schizophrenia and autism overlap, and it has been
suggested that prenatal infection may be a general risk factor that confers vulnerability to
multiple disorders, with the specific disorder determined by genetic or other
environmental factors (Harvey and Boksa, 2012; Meyer, 2013).
There are many effects of PPA and SCFAs on biological systems that are
favourable, including maintenance of normal immune function (Al-Lahham et al., 2010;
Brestoff and Artis, 2013). However, shifts in the microbiome composition, as with
alterations in diet or antibiotic use, may lead to increased levels of PPA, LPS, and other
enteric metabolites that could induce inflammatory responses, alter neurodevelopment,
and influence behaviour. Indeed, impaired carbohydrate digestion and increased
behavioural symptoms in children with ASD following carbohydrate consumption have
been reported (Adams et al., 2011; Jyonouchi, 2009). Colonization of the gut by microbes
occurs throughout early development and perturbations in this process leading to gut
dysbiosis may contribute to the development of neuropsychiatric disorders, including
autism.
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